日本臨牀　82/増刊3　食道癌2024

出版社： 日本臨牀社
発行日： 2024-05-31
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 食道癌2024
電子書籍版： 2024-05-31 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

24,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

24,200 円(税込)

購入する

目次

  • 特集　食道癌2024
    　　　―基礎・臨床の最新動向―

    序　文

    I．総　論
    　1．食道癌―これまでの診療と今後の展望
    　2．食道がん手術に必要な縦隔解剖―リンパ節の位置関係と周囲臓器のミクロ解剖―

    II．食道癌の疫学
    　1．食道癌の罹患率と死亡率の現況（本邦）
    　2．食道癌の罹患率と死亡率の現況（海外）
    　3．食道癌のリスク因子（アルコール除く）
    　4．アルコールと食道癌
    　5．食道癌における多発癌と重複癌
    　6．食道癌の全国治療成績

    III．食道癌の生物学
    　1．食道扁平上皮癌の発生機序と治療への応用
    　2．バレット腺癌の発生機序と治療への応用
    　3．網羅的ゲノム解析の現状
    　4．高齢者でのエピジェネティクスの関与
    　5．食道癌の腫瘍免疫微小環境
    　6．食道癌における腸内細菌叢の重要性

    IV．食道腫瘍の病理
    　1．SIN－扁平上皮内腫瘍
    　2．SSBE—腺癌
    　3．特殊組織型腫瘍（非上皮性腫瘍を含む）

    V．食道癌「取扱い規約」の要点
    　1.「食道癌取扱い規約」第12版改訂の要点
    　2.「食道癌取扱い規約」第12版改訂の詳細
    　3．食道癌「取扱い規約」第12版改訂の問題点
    　4．UICC-TNM分類と「食道癌取扱い規約」

    VI．食道癌「診断治療ガイドライン」の要点
    　1.「食道癌診療ガイドライン」の変遷と今後
    　2.「食道癌診療ガイドライン」2022年版改訂の要点
    　3．作成方法論からみた「食道癌診療ガイドライン」2022年版の特徴と評価
    　4．海外ガイドラインとの比較

    VII．食道癌の診断
    　1．食道癌深達度診断・リンパ節診断の進歩
    　2．食道造影検査の重要性と今後
    　3．内視鏡検査
    　　（1）通常観察
    　　（2）経鼻内視鏡による診断
    　　（3）食道表在癌（扁平上皮癌）に対する拡大内視鏡観察
    　　（4）Barrett食道癌の内視鏡診断
    　4．超音波内視鏡検査の進歩
    　5．CT診断の進歩
    　6．MRI診断の進歩
    　7．PET診断の進歩
    　8．食道癌腫瘍マーカー
    　9．食道癌再発早期診断のための新しい検査法

    VIII．食道癌の治療
    　1．食道癌の治療戦略：概論
    　　（1）頸部食道癌
    　　（2）胸部食道癌
    　　（3）食道胃接合部癌
    　2．内視鏡的治療
    　　（1）食道癌内視鏡的治療の適応の変遷
    　　（2）食道癌内視鏡的治療の進歩
    　　（3）食道表在癌ESD後有害事象の対策・予防
    　3．外科治療
    　　（1）頸部食道癌に対する手術・高齢者への適応
    　　（2）胸部食道癌に対する手術
    　　　　1）胸部食道がん手術・高齢者への適応と対応
    　　　　2）胸腔鏡下食道切除術
    　　　　　　(1) 側臥位の有用性と今後
    　　　　　　(2) 腹臥位の有用性と今後
    　　　　3）縦隔鏡下食道切除
    　　　　4）胸部食道癌に対するロボット支援食道切除術
    　　（3）食道胃接合部癌に対する手術
    　　　　1）左開胸開腹食道切除術
    　　　　2）経裂孔的食道切除術
    　　　　　　(1) 開腹手術
    　　　　　　(2) 腹腔鏡手術
    　　（4）食道再建
    　　　　1）胃を用いた再建法の進歩
    　　　　2）小腸を用いた再建の進歩
    　　　　3）大腸を用いた再建法
    　　　　4）食道胃接合部癌における下部食道切除の再建法
    　　（5）サルベージ手術とコンバージョン手術
    　　（6）食道癌手術の周術期管理
    　　（7）サルコペニア・フレイル対策
    　　（8）合併症に対する治療
    　　（9）医療安全から見た食道癌手術
    　4．薬物療法
    　　（1）高齢者に対する化学療法の考え方
    　　（2）周術期の化学療法
    　　（3）進行・再発食道癌に対する化学療法
    　　（4）免疫チェックポイント阻害薬の適応と実際
    　5．放射線療法
    　　（1）高齢者に対する放射線療法の考え方
    　　（2）食道癌に対する放射線単独療法
    　　（3）陽子線治療の現状と展望
    　　（4）食道癌に対する重粒子線治療の現状と展望
    　6．化学放射線療法
    　　（1）高齢者に対する化学放射線療法の考え方
    　　（2）術前補助化学放射線療法
    　　（3）根治的化学放射線療法
    　7．光線力学的療法の現状と展望
    　8．姑息治療の進歩
    　9．ワクチン療法・ミサイル療法の今後の展開

    IX．再発食道癌の治療
    　1．高齢者食道癌の再発治療
    　2．再発食道癌における化学療法・化学放射線療法
    　3．再発食道癌に対する外科治療

    X．食道癌における臨床試験
    　1．本邦における食道癌多施設共同研究の概要と成績
    　2．海外における食道癌多施設共同研究の概要と成績

    XI．特　論
    　1．食道癌に対する術前治療の病理組織学的治療効果判定
    　2．気管・気管支浸潤への治療の進歩と展望
    　3．高齢者機能評価のあり方と治療選択～認知機能評価も含めて～
    　4．新規治療開発研究
    　5．重複癌の治療
    　6．食道癌におけるがんパネル検査の有用性と今後
    　7．食道癌手術におけるCST（cadaver surgical training）の現状と今後
    　8．食道癌治療におけるリキッドバイオプシーの有用性

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.3 掲載の参考文献
1) 臨床・病理食道癌取扱い規約第12版(日本食道学会編) 金原出版, 2022.
 
2) 食道癌診療ガイドライン2022年版(日本食道学会編) 金原出版, 2022.
 

I 総論

P.12 掲載の参考文献
1) 赤坂裕三, 奥田順一, 井田和徳, ほか:食道ルゴール法の基礎と臨床応用について-染色機序の検査及び食道癌診断に関する試みについて. Gastroenterol Endosc 18:84-91, 1976.
 
2) 永尾重昭:消化器内視鏡の発展-内視鏡機器の進歩. Gastroenterol Endosc 62(Suppl 3):2371-2374, 2020.
 
3) Makuuchi H, Shimada H, Mizutani K, et al:Endoscopic criteria for invasive depth of superficial esophageal cancer. Dig Endosc 9:110-115, 1997.
 
4) 島田英雄, 千野修, 西隆之, ほか:食道表在癌の深達度診断-通常内視鏡診断. 胃と腸 50:539-552, 2015.
 
5) Inoue H, Honda T, Nagai K et al:Ultra-high magnification endoscopic observation of carcinoma in situ of the esophagus. Dig Endosc 9:16-17, 1997.
 
6) Arima M, Tada M, Arima H:Evaluation of microvascular patterns of superficial esophageal cancers by magnifying endoscopy. Esopahagus 2:191-197, 2005.
 
7) 日本食道学会(編):臨床・病理食道癌取扱い規約 第12版, 金原出版, 2022.
 
8) 竹内学, 橋本哲, 小林正明, ほか:食道表在癌の深達度診断-拡大観察の有用性と留意点. 胃と腸 50:553-562, 2015.
 
9) 横山顕:食道表在癌の危険因子. 胃と腸 46:561-570, 2011.
 
10) Katada C, Yokoyama T, Yano T, et al:Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. Gastroenterology 151:860-869.e7, 2016.
 
11) Horie Y, Yoshio T, Aoyama K, et al:Diagnostic outcomes of esophageal cancer by artificial intelligence using convolutional neural networks. Gastrointest Endosc 89:25-32, 2019.
PubMed
12) Kumagai Y, Kawada K, Yamazaki S, et al:Endocytoscopic observation for esophageal squamous cell carcinoma:Can biopsy histology be omitted? Dis Esophagus 22:505-512, 2009.
PubMed
13) 石原立, 有馬美和子, 飯塚敏郎, ほか:食道癌に対するEMR/ESDガイドライン. Gastroenterol Endosc 62:221-271, 2020.
 
14) 小野裕之:消化管癌ESDの歴史・現況と展望. 日消誌 114:971-977, 2017.
Medical*Online
15) Makuuchi H, et al:Endoscopicmucosal resection for early esophageal cancer -indication and techniques. Dig Endosc 8:175-179, 1996.
 
16) 小山恒夫, 菊池勇一, 友利彰寿, ほか:食道癌に対するEMRの選択方法:新しいEMR手技-Hooking EMR method の有用性. 臨床消化器内科 16:1609-1615, 2001.
 
17) Shimada H, Makuuchi M, Ozawa S, et al:Technique of the double-channel ESD method performed with an EEMR tube. Esophagus 8:67-70, 2011.
 
18) 大澤達:外科医生活45年-修業時代と指導医時代の思い出. 臨床外科 21:1400-1402, 1966.
 
19) 中山恒明:胸部食道全剔出術. 日本外科学会誌 51:310-315, 1950.
 
20) 赤倉一郎:食道癌治療のあゆみと共に. 日胸外会誌 15:87-92, 1967.
 
21) Ohkura Y, Miyata H, Konno H, et al:Development of a model predicting the risk of eight major postoperative complications after esophagectomy based on 10 826 cases in the Japan National Clinical Database. J Surg Oncol 121:313-321, 2020.
 
22) Isono K, Sato H, Nakayama K:Results of a nationwide study on the three-field lymph node dissection of esophageal cancer. Oncology 48:411-420, 1991.
 
23) Akaishi T, Kaneda I, Higuchi N, et al:Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy. J Thorac Cardiovasc Surg 112:1533-1541, 1996.
PubMed
24) Palanivelu C, Prakash A, Senthikumar R, et al:Minimal invasive esophagectomy:thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 203:7-16, 2006.
 
25) 小澤壯治:本邦における食道癌外科治療の歩みと将来展望. 日臨外会誌 82:1271-1280, 2021.
 
26) Suda K, Ishida Y, Kawamura Y, et al:Robot-assisted thoracoscopic lymphadenectomy along the left recurrent laryngeal nerve for esophageal squamous cell carcinoma in the prone position:technical report and short-term outcomes. World J Surg 36:1608-1616, 2012.
PubMed
27) 野間和弘:ロボット支援鏡視下食道腫瘍手術. 臨外 78:925-929, 2023.
 
28) 須田康一, 柴崎晋, 田中毅, ほか:ロボット手術の現状と将来展望-上部消化管外科医の立場から-現代医学 69:66-73, 2022.
Medical*Online
29) 葛西森夫:食道癌の外科的治療-成績向上の道. 日外会誌 81:845-853, 1980.
 
30) Ando N, Kato H, Igaki H, et al:A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68-74, 2012.
 
31) 日本食道学会(編):食道癌診療ガイドライン 2022年版, 金原出版, 2022.
 
P.22 掲載の参考文献
1) Torek F:The first successful case of resection of the thoracic portion of the oesophagus for carcinoma. Surg Gynecol Obste 16:614-617, 1913.
 
2) Moore KL, Persaud TVN, Torchia MG:The Developing Human-E-Book, Elsevier Health Sciences, 2018.
 
3) Perlemuter L, Waligora J:臨床解剖学ノート 胸部編(佐藤達夫, 高橋孝訳), 中央洋書, 1984.
 
4) Matsubara T, Ueda M, Nagao N, et al:Cervicothoracic approach for total mesoesophageal dissection in cancer of the thoracic esophagus. J Am Coll Surg 187:238-245, 1998.
PubMed
5) Tokairin Y, Kawamura Y, Muro S, et al:Histological study of the thin membranous dense connective tissues around the curving portion of the bilateral recurrent laryngeal nerves. Esophagus 20:410-419, 2023.
PubMed
6) Tokairin Y, Nagai K, Kawamura Y, et al:Histological study of the thin membranous dense connective tissue around the middle and lower thoracic esophagus, caudal to the bifurcation of the trachea. Gen Thorac Cardiovasc Surg 69:983-992, 2021.
 
7) Cuesta MA, Weijs TJ, Bleys RL, et al:A new concept of the anatomy of the thoracic oesophagus:the meso-oesophagus. Observational study during thoracoscopic esophagectomy. Surg Endosc 29:2576-2582, 2015.
PubMed
8) Adachi B, Kihara T:Anatomie der Japaner:III Das Lymphgefaszsystem der Japaner, von Takusaburo Kihara;erste Lieferung:Der Ductus thoracicus der Japaner. Kyoto University, 1953.
 
9) 大谷修, 大谷裕子:リンパ管の構造-とくに平滑筋とそのリンパ輸送における重要性. 医学のあゆみ 262:1147-1150, 2017.
Medical*Online
10) 雨宮隆太, 清嶋護之, 鏑木孝之:初心者のための気管支鏡所見の読み方. 気管支学 38:328-333, 2016.
Medical*Online
11) Salassa JR, Pearson BW, Payne WS:Gross and microscopical blood supply of the trachea. Ann Thorac Surg 24:100-107, 1977.
PubMed
12) Nishiwaki N, Noma K, Maeda N, et al:High incidence of tracheobronchial diverticulum in esophageal cancer patients:a retrospective survey alerting pitfall during thoracoscopic esophagectomy. Gen Thorac Cardiovasc Surg 68:1018-1023, 2020.
PubMed
13) Hiroshi Y, Ken-Ichiro T, Masashi U:Right top pulmonary veins associated with lung incomplete fissure and displaced bronchus:a retrospective study using multidetector computed tomography. Gen Thorac Cardiovasc Surg 69:290-296, 2021.
PubMed
14) Jais P, Haissaguerre M, Shah DC, et al:A focal source of atrial fibrillation treated by discrete radiofrequency ablation. Circulation 95:572-576, 1997.
PubMed
15) Haissaguerre M, Jais P, Shah DC, et al:Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med 339:659-666, 1998.
PubMed
16) Toniato A, Mazzarotto R, Piotto A, et al:Identification of the nonrecurrent laryngeal nerve during thyroid surgery:20-year experience. World J Surg 28:659-661, 2004.
PubMed
17) Weijs TJ, Ruurda JP, Luyer MD, et al:Topography and extent of pulmonary vagus nerve supply with respect to transthoracic oesophagectomy. J Anat 227:431-439, 2015.
PubMed
18) Netter FH:Atlas of Human Anatomy, fourth edition, Saunders, 2006.
 

II 食道癌の疫学

P.29 掲載の参考文献
1) 国立がん研究センター:がん情報サービス「がん統計」(全国がん登録).
 
2) 国立がん研究センター:がん情報サービス「がん統計」(全国がん罹患モニタリング集計(MCIJ)).
 
3) 国立がん研究センター:がん情報サービス「がん統計」(厚生労働省人口動態統計).
 
4) 国立がん研究センター:がん情報サービス「がん統計」(人口動態統計).
 
5) 全国がん罹患モニタリング集計 2009-2011年生存率報告, 国立研究開発法人国立がん研究センターがん対策情報センター, 2020.
 
6) Ito Y, Miyashiro I, Ito H, et al:Long-term survival and conditional survival of cancer patients in Japan using population-based cancer registry data. Cancer Sci 105:1480-1486, 2014.
PubMed
P.34 掲載の参考文献
1) International Agency for Research on Cancer, WHO:The Global Cancer Observatory, 2023. [http://globocan.iarc.fr/Default.aspx]
 
2) Sung H, Ferlay J, Siegel RL, et al:Global Cancer Statistics 2020:GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209-249, 2021.
PubMed
3) Morgan E, Soerjomataram I, Rumgay H, et al:The Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020 and Projections to 2040:New Estimates From GLOBOCAN 2020. Gastroenterology 163:649-658.e2, 2022.
 
4) Szumilo J:[Epidemiology and risk factors of the esophageal squamous cell carcinoma]. Pol Merkur Lekarski 26:82-85, 2009.
PubMed
5) Malhotra GK, Yanala U, Ravipati A, et al:Global trends in esophageal cancer. J Surg Oncol 115:564-579, 2017.
PubMed
6) Wong MCS, Hamilton W, Whiteman DC, et al:Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci Rep 8:4522, 2018.
PubMed
7) Morita M, Kumashiro R, Kubo N, et al:Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus:epidemiology, clinical findings, and prevention. Int J Clin Oncol 15:126-134, 2010.
PubMed
8) Yokoyama A, Mizukami T, Yokoyama T:Genetic polymorphisms of alcohol dehydrogense-1B and aldehyde dehydrogenase-2, alcohol flushing, mean corpuscular volume, and aerodigestive tract neoplasia in Japanese drinkers. Adv Exp Med Biol 815:265-279, 2015.
PubMed
9) Li H, Borinskaya S, Yoshimura K, et al:Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet 73:335-345, 2009.
PubMed
10) Castellsague X, Munoz N, De Stefani E, et al:Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South America. Int J Cancer 88:658-664, 2000.
PubMed
11) Lin J, Zeng R, Cao W, et al:Hot beverage and food intake and esophageal cancer in southern China. Asian Pac J Cancer Prev 12:2189-2192, 2011.
PubMed
12) Polyzos SA, Zeglinas C, Artemaki F, et al:Helicobacter pylori infection and esophageal adenocarcinoma:a review and a personal view. Ann Gastroenterol 31:8-13, 2018.
 
13) Lin Y, Wang HL, Fang K, et al:International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030. Esophagus 19:560-568, 2022.
 
P.38 掲載の参考文献
1) Ishiguro S, Sasazuki S, Inoue M, et al:Effect of alcohol consumption, cigarette smoking and flushing response on esophageal cancer risk:a population-based cohort study (JPHC study). Cancer Lett 275:240-246, 2009.
 
2) Oze I, Charvat H, Matsuo K, et al:Revisit of an unanswered question by pooled analysis of eight cohort studies in Japan:Does cigarette smoking and alcohol drinking have interaction for the risk of esophageal cancer? Cancer Med 8:6414-6425, 2019.
PubMed
3) Prabhu A, Obi KO, Rubenstein JH:The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma:a meta-analysis. Am J Gastroenterol 109:822-827, 2014.
PubMed
4) Wang L, Zhu D, Zhang C, et al:Mutations of O6-methylguanine-DNA methyltransferase gene in esophageal cancer tissues from Northern China. Int J Cancer 71:719-723, 1997.
PubMed
5) Abnet CC, Lai B, Qiao YL, et al:Zinc concentration in esophageal biopsy specimens measured by xray fluorescence and esophageal cancer risk. J Natl Cancer Inst 97:301-306, 2005.
 
6) Liu J, Wang J, Leng Y, et al:Intake of fruit and vegetables and risk of esophageal squamous cell carcinoma:a meta-analysis of observational studies. Int J Cancer 133:473-485, 2013.
PubMed
7) Yamaji T, Inoue M, Sasazuki S, et al:Fruit and vegetable consumption and squamous cell carcinoma of the esophagus in Japan:the JPHC study. Int J Cancer 123:1935-1940, 2008.
PubMed
8) Mohammadpour B, Rouhi S, Khodabandehloo M, et al:Prevalence and Association of Human Papillomavirus with Esophageal Squamous Cell Carcinoma in Iran:A Systematic Review and Meta-Analysis. Iran J Public Health 48:1215-1226, 2019.
PubMed
9) Deniz Z, Uraz S, Holem R, et al:Human Papillomavirus Infection and Oropharyngeal and Gastrointestinal Cancers:A Causal Relationship? Diseases 10:94, 2022.
PubMed
10) 幕内博康, 島田英雄, 千野修, ほか:食道癌手術症例にみられる他臓器重複癌. EMR症例も含めて. 胃と腸 38:317-330, 2003.
 
11) Katada C, Yokoyama T, Yano T, et al:Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. Gastroenterology 151:860-869.e7, 2016.
 
12) Hvid-Jensen F, Pedersen L, Drewes AM, et al:Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med 365:1375-1383, 2011.
 
13) Tramacere I, La Vecchia C, Negri E:Tobacco smoking and esophageal and gastric cardia adenocarcinoma:a meta-analysis. Epidemiology 22:344-349, 2011.
PubMed
14) Rajendra S, Wang B, Snow ET, et al:Transcriptionally active human papillomavirus is strongly associated with Barrett's dysplasia and esophageal adenocarcinoma. Am J Gastroenterol 108:1082-1093, 2013.
 
15) Tramacere I, Pelucchi C, Bagnardi V, et al:A meta-analysis on alcohol drinking and esophageal and gastric cardia adenocarcinoma risk. Ann Oncol 23:287-297, 2012.
PubMed
16) Singh S, Sharma AN, Murad MH, et al:Central adiposity is associated with increased risk of esophageal inflammation, metaplasia, and adenocarcinoma:a systematic review and meta-analysis. Clin Gastroenterol Hepatol 11:1399-1412.e7, 2013.
 
P.44 掲載の参考文献
1) 横山顕:食道扁平上皮癌の危険因子と頭頸部・胃を含むfield cancerization. 日消誌 115:868-880, 2018.
Medical*Online
2) Koyanagi YN, Ito H, Oze I, et al:Development of a prediction model and estimation of cumulative risk for upper aerodigestive tract cancer on the basis of the aldehyde dehydrogenase 2 genotype and alcohol consumption in a Japanese population. Eur J Cancer Prev 26:38-47, 2017.
 
3) Yang SJ, Yokoyama A, Yokoyama T, et al:Relationship between genetic polymorphisms of ALDH2 and ADH1B and esophageal cancer risk:a meta-analysis. World J Gastroenterol 16:4210-4220, 2010.
 
4) Yokoyama T, Yokoyama A, Kumagai Y, et al:Health risk appraisal models for mass screening of esophageal cancer in Japanese men. Cancer Epidemiol Biomarkers Prev 17:2846-2854, 2008.
PubMed
5) Yokoyama A, Katada C, Yokoyama S, et al:Alcohol abstinence and risk assessment for second esophageal cancer in Japanese men after mucosectomy for early esophageal cancer. PLoS One 12:e0175182, 2017.
 
6) Urabe Y, Kagemoto K, Nakamura K, et al:Construction of a risk model for the development of metachronous squamous cell carcinoma after endoscopic resection of esopahageal squamous cell carcinoma. Esophagus 16:141-146, 2019.
PubMed
7) Abiko S, Shimizu Y, Miyamoto S, et al:Risk assessment of metachronous squamous cell carcinoma after endoscopic resection for esophageal carcinoma based on the genetic polymorphisms of alcoholdehydrogense-1B aldehyde dehydrogenase-2:temperance reduces the risk. J Gastroenterol 53:1120-1130, 2018.
 
8) Yokoyama A, Katada C, Yokoyama T, et al:The Alcohol Use Disorders Identification Test and the risk of metachronous cancer after endoscopic resection of esophageal cancer. Carcinogenesis 41:1049-1056, 2020.
PubMed
9) Katada C, Yokoyama T, Yano T, et al:Association between macrocytosis and metachronous squamous cell carcinoma of the esophagus after endoscopic resection in men with early esophageal squamous cell carcinoma. Esophagus 17:149-158, 2020.
PubMed
10) Hirao M, Katada C, Yokoyama T, et al:Metachronous primary gastric cancer after endoscopic resection in patients with esophageal squamous cell carcinoma. Gastric Cancer 26:988-1001, 2023.
PubMed
11) Shiba S, Nakamoto N, Chu PS, et al:Acetaldehyde exposure underlies functional defects in monocytes induced by excessive alcohol consumption. Sci Rep 11:13690, 2021.
PubMed
12) Hirata K, Yokoyama A, Nakamura R, et al:Soft palatal melanosis, a simple predictor for neoplasia in the upper aerodigestive tract in Japanese alcoholic men. Cancer Sci 108:1058-1064, 2017.
PubMed
13) Katada C, Yokoyama T, Yano T, et al:Alcohol consumption and multiple dysplastic lesions increase risk of squamous cell carcinoma in the esophagus, head, and neck. Gastroenterology 151:860-869.e7, 2016.
 
14) Muto M, Katada C, Yokoyama T, et al:Field Effect of Alcohol, Cigarette Smoking, and Their Cessation on the Development of Multiple Dysplastic Lesions and Squamous Cell Carcinoma:A Long-term Multicenter Cohort Study. Gastro Hep Advances 1:265-276, 2022.
PubMed
15) Hori K, Katada C, Okada H, et al:Association between continuous cessation or reduction of drinking alcohol and improvement of multiple dysplastic lesions in patients with esophageal squamous cell carcinoma after endoscopic resection. Esophagus 21:31-40, 2024.
PubMed
16) Yokoyama A, Kimura M, Yoshimura A, et al:Nonsmoking after simultaneous alcohol abstinence and smoking cessation program was associated with better drinking status outcome in Japanese alcohol-dependent men:A prospective follow-up study. PLoS One 18:e0282992, 2023.
 
17) Yokoyama A, Yokoyama T, Omori T, et al:Endoscopic screening using esophageal iodine staining and genotypes of ADH1B and ALDH2 in Japanese alcohol-dependent women. PLoS One 14:e0210546, 2019.
PubMed
18) Yokoyama A, Omori T, Yokoyama T:Changing trends in cancer incidence of upper aerodigestive tract and stomach in Japanese alcohol-dependent men (1993-2018). Cancer Med 9:837-846, 2020.
PubMed
P.50 掲載の参考文献
1) 日本食道学会(編):臨床・病理 食道癌取り扱い規約 第12版, p19, 金原出版, 2022.
 
2) Slaughter DP, Southwick HW, Smejkal W:Field cancerization in oral stratified squamous epithelium;clinical implications of multicentric origin. Cancer 6:963-968, 1953.
PubMed
3) Kuwano H, Ueo H, Sugimachi K, et al:Glandular or mucus-secreting components in squamous cell carcinoma of the esophagus. Cancer 56:514-518, 1985.
 
4) Kagemoto K, Urabe Y, Miwata T, et al:ADH1B and ALDH2 are associated with metachronous SCC after endoscopic submucosal dissection of esophageal squamous cell carcinoma. Cancer Med 5:1397-1404, 2016.
PubMed
5) Tajiri A, Ishihara R, Sakurai H, et al:Clinical features of superficial esophagus squamous cell carcinoma according to alcohol-degrading enzyme ADH1B and ALDH2 genotypes. J Gastroenterol 57:630-639, 2022.
PubMed
6) Katada C, Yokoyama T, Yano T, et al:Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. Gastroenterology 151:860-869.e7, 2016.
 
7) Muto M, Hitomi Y, Ohtsu A, et al:Association of aldehyde dehydrogenase 2 gene polymorphism with multiple oesophageal dysplasia in head and neck cancer patients. Gut 47:256-261, 2000.
PubMed
8) The Japanese Society for Esophageal Diseases:Comprehensive Registry of Esophageal Cancer in Japan, 2012.
 
9) The Japanese Society for Esophageal Diseases:Comprehensive Registry of Esophageal Cancer in Japan (1988～1994) 1st Edition, 2000.
 
10) The Japanese Society for Esophageal Diseases:Comprehensive Registry of Esophageal Cancer in Japan (1995, 1996, 1997) 2nd Edition, 2001.
 
11) The Japanese Society for Esophageal Diseases:Comprehensive Registry of Esophageal Cancer in Japan (1998, 1999) 3rd Edition, 2002.
 
12) The Registration Committee for Esophageal Cancer, The Japan Esophageal Society:Comprehensive Registry of Esophageal Cancer in Japan, 2008.
 
13) The Registration Committee for Esophageal Cancer, The Japan Esophageal Society:Comprehensive Registry of Esophageal Cancer in Japan, 2009.
PubMed
14) The Registration Committee for Esophageal Cancer, The Japan Esophageal Society:Comprehensive Registry of Esophageal Cancer in Japan, 2010.
PubMed
15) The Registration Committee for Esophageal Cancer, The Japan Esophageal Society:Comprehensive Registry of Esophageal Cancer in Japan, 2011.
 
P.57 掲載の参考文献
1) 押切太郎, 中村哲, 掛地吉弘:Big dataからみる食道癌-食道癌全国登録とNCD-. 日本臨牀 76(増刊号8:食道癌第2版), p54-59, 2018.
 
2) 食道癌診療ガイドライン 2022年版(日本食道学会編), 金原出版, 2022.
 
3) Kajiwara Y, Takahashi A, Ueno H, et al:Annual report on National Clinical Database 2020 for gastroenterological surgery in Japan. Ann Gastroenterol Surg 7:367-406, 2023.
PubMed
4) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
5) 藤也寸志, 松原久裕:食道外科におけるNCDデータの有効活用. 消化器外科 39:899-906, 2016.
 
6) Sasaki A, Tachimori H, Akiyama Y, et al:Risk model for mortality associated with esophagectomy via a thoracic approach based on data from the Japanese National Clinical Database on malignant esophageal tumors. Surg Today 53:73-81, 2023.
 
7) Japanese Society of Esophageal Diseases:Comprehensive registry of esophageal cancer in Japan, 1999. Esophagus 2:43-69, 2005.
 
8) Tachimori Y, Ozawa S, Numasaki H, et al:Comprehensive Registry of Esophageal Cancer in Japan, 2011. Esophagus 15:127-152, 2018.
PubMed
9) Kato K, Ito Y, Nozaki I, et al:Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 161:1878-1886.e2, 2021.
 
10) Minsky BD, Pajak TF, Ginsberg RJ, et al:INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer:high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167-1174, 2002.
PubMed
11) Takeuchi H, Ito Y, Machida R, et al:A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys 114:454-462, 2022.
PubMed
12) Oshikiri T, Goto H, Kato T, et al:Proposed modification of the eighth edition of the AJCC-ypTNM staging system of esophageal squamous cell cancer treated with neoadjuvant chemotherapy:Unification of the AJCC staging system and the Japanese classification. Eur J Surg Oncol 48:1760-1767, 2022.
PubMed

III 食道癌の生物学

P.66 掲載の参考文献
1) Curtius K, Wright NA, Graham TA:An evolutionary perspective on field cancerization. Nat Rev Cancer 18:19-32, 2018.
 
2) Yokoyama A, Kakiuchi N, Yoshizato T, et al:Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565:312-317, 2019.
PubMed
3) Cancer Genome Atlas Research Network;Analysis Working Group:Asan University;BC Cancer Agency, et al:Integrated genomic characterization of oesophageal carcinoma. Nature 541:169-175, 2017.
 
4) Wang LD, Zhou FY, Li XM, et al:Genome-wide association study of esophageal squamous cell carcinoma in Chinese subjects identifies susceptibility loci at PLCE1 and C20orf54. Nat Genet 42:759-763, 2010.
PubMed
5) Tanaka F, Yamamoto K, Suzuki S, et al:Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 59:1457-1464, 2010.
PubMed
6) Blaydon DC, Etheridge SL, Risk JM, et al:RHBDF2 mutations are associated with tylosis, a familial esophageal cancer syndrome. Am J Hum Genet 90:340-346, 2012.
PubMed
7) Steevens J, Schouten LJ, Goldbohm RA, et al:Alcohol consumption, cigarette smoking and risk of subtypes of oesophageal and gastric cancer:a prospective cohort study. Gut 59:39-48, 2010.
PubMed
8) Jarl J, Gerdtham UG:Time pattern of reduction in risk of oesophageal cancer following alcohol cessation-a meta-analysis. Addiction 107:1234-1243, 2012.
PubMed
9) Abiko S, Shimizu Y, Miyamoto S, et al:Risk assessment of metachronous squamous cell carcinoma after endoscopic resection for esophageal carcinoma based on the genetic polymorphisms of alcoholdehydrogense-1B aldehyde dehydrogenase-2:temperance reduces the risk. J Gastroenterol 53:1120-1130, 2018.
 
10) Bosetti C, Gallus S, Garavello W, et al:Smoking cessation and the risk of oesophageal cancer:An overview of published studies. Oral Oncol 42:957-964, 2006.
PubMed
11) Yuan L, Shen P, Zheng S, et al:Analysis of living habit risk factors for esophageal cancer in central China:A bi-center case-control study. Front Oncol 13:1077598, 2023.
 
12) Sakai M, Kitagawa Y, Saeki H, et al:Fruit and vegetable consumption and risk of esophageal cancer in the Asian region:a systematic review and meta-analysis. Esophagus 19:27-38, 2022.
 
13) Wang SM, Freedman ND, Katki HA, et al:Gastroesophageal reflux disease:A risk factor for laryngeal squamous cell carcinoma and esophageal squamous cell carcinoma in the NIH-AARP Diet and Health Study cohort. Cancer 127:1871-1879, 2021.
PubMed
14) Dunaway PM, Wong RK:Risk and surveillance intervals for squamous cell carcinoma in achalasia. Gastrointest Endosc Clin N Am 11:425-434, ix, 2001.
 
15) Minami H, Yamaguchi N, Matsushima K, et al:Improvement of endocytoscopic findings after per oral endoscopic myotomy (POEM) in esophageal achalasia;does POEM reduce the risk of developing esophageal carcinoma? Per oral endoscopic myotomy, endocytoscopy and carcinogenesis. BMC Gastroenterol 13:22, 2013.
PubMed
16) Petrick JL, Wyss AB, Butler AM, et al:Prevalence of human papillomavirus among oesophageal squamous cell carcinoma cases:systematic review and meta-analysis. Br J Cancer 110:2369-2377, 2014.
PubMed
P.72 掲載の参考文献
1) di Pietro M, Trudgill NJ, Vasileiou M, et al:National Institute for Health and Care Excellence (NICE) guidance on monitoring and management of Barrett's oesophagus and stage I oesophageal adenocarcinoma. Gut:gutjnl-2023-331557, 2024. (DOI:10.1136/gutjnl-2023-331557)
 
2) Shaheen NJ, Falk GW, Iyer PG, et al:Diagnosis and Management of Barrett's Esophagus:An Updated ACG Guideline. Am J Gastroenterol 117:559-587, 2022.
 
3) Fitzgerald RC, di Pietro M, Ragunath K, et al:British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63:7-42, 2014.
 
4) 日本食道学会(編):食道癌取扱い規約 第12版, 金原出版, 2022.
 
5) Bhat S, Coleman HG, Yousef F, et al:Risk of malignant progression in Barrett's esophagus patients:results from a large population-based study. J Natl Cancer Inst 103:1049-1057, 2011.
 
6) Pohl H, Pech O, Arash H, et al:Length of Barrett's oesophagus and cancer risk:implications from a large sample of patients with early oesophageal adenocarcinoma. Gut 65:196-201, 2016.
 
7) Souza RF, Krishnan K, Spechler SJ:Acid, bile, and CDX:the ABCs of making Barrett's metaplasia. Am J Physiol Gastrointest Liver Physiol 295:G211-G218, 2008.
 
8) Mukaisho KI, Kanai S, Kushima R, et al:Barretts's carcinogenesis. Pathol Int 69:319-330, 2019.
PubMed
9) Terasaki M, Totsuka Y, Nishimura K, et al:Detection of endogenous DNA adducts, Ocarboxymethyl-2'-deoxyguanosine and 3-ethanesulfonic acid-2'-deoxycytidine, in the rat stomach after duodenal reflux. Cancer Sci 99:1741-1746, 2008.
 
10) Araki Y, Mukaisyo K, Sugihara H, et al:Detection of N-nitroso-bile acids at 285 nm in reverse-phase HPLC. J Sep Sci 31:2827-2830, 2008.
 
11) Takubo K, Aida J, Naomoto Y, et al:Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 40:65-74, 2009.
PubMed
12) Kushima R, Mukaisho KI, Takemura S, et al:[Barrett's esophagus:analyses from human and experimental animal studies]. Pathologe 34:138-147, 2013.
 
13) Nowicki-Osuch K, Zhuang L, Jammula S, et al:Molecular phenotyping reveals the identity of Barrett's esophagus and its malignant transition. Science 373:760-767, 2021.
 
14) Sugano K, Spechler SJ, El-Omar EM, et al:Kyoto international consensus report on anatomy, pathophysiology and clinical significance of the gastro-oesophageal junction. Gut 71:1488-1514, 2022.
PubMed
15) 庄司絢香, 石原立, 松浦倫子, ほか:食道胃接合部の新展開食道胃接合部の腫瘍表在型食道胃接合部癌の転移リスクとは. 特集 消化器内視鏡 32:758-764, 2020.
 
P.81 掲載の参考文献
1) Chang J, Zhao X, Wang Y, et al:Genomic alterations driving precancerous to cancerous lesions in esophageal cancer development. Cancer Cell 41:2038-2050.e5, 2023.
 
2) Chang J, Tan W, Ling Z, et al:Genomic analysis of oesophageal squamous-cell carcinoma identifies alcohol drinking-related mutation signature and genomic alterations. Nat Commun 8:15290, 2017.
PubMed
3) Dulak AM, Stojanov P, Peng S, et al:Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45:478-486, 2013.
PubMed
4) Zhao J, Jia X, Li Q, et al:Genomic and transcriptional characterization of early esophageal squamous cell carcinoma. BMC Med Genomics 16:153, 2023.
 
5) Sawada G, Niida A, Uchi R, et al:Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. Gastroenterology 150:1171-1182, 2016.
 
6) Song Y, Li L, Ou Y, et al:Identification of genomic alterations in oesophageal squamous cell cancer. Nature 509:91-95, 2014.
 
7) Liu X, Zhang M, Ying S, et al:Genetic Alterations in Esophageal Tissues From Squamous Dysplasia to Carcinoma. Gastroenterology 153:166-177, 2017.
 
8) Cancer Genome Atlas Research Network;Analysis Working Group:Asan University;BC Cancer Agency, et al:Integrated genomic characterization of oesophageal carcinoma. Nature 541:169-175, 2017.
 
9) Cheng C, Zhou Y, Li H, et al:Whole-Genome Sequencing Reveals Diverse Models of Structural Variations in Esophageal Squamous Cell Carcinoma. Am J Hum Genet 98:256-274, 2016.
 
10) Secrier M, Li X, de Silva N, et al:Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet 48:1131-1141, 2016.
 
11) Agrawal N, Jiao Y, Bettegowda C, et al:Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2:899-905, 2012.
PubMed
12) Kumar S, Zhao J, Talluri S, et al:Elevated APE1 Dysregulates Homologous Recombination and Cell Cycle Driving Genomic Evolution, Tumorigenesis, and Chemoresistance in Esophageal Adenocarcinoma. Gastroenterology 165:357-373, 2023.
PubMed
13) Li S, Yuan L, Xu ZY, et al:Integrative proteomic characterization of adenocarcinoma of esophagogastric junction. Nat Commun 14:778, 2023.
 
14) Tanaka F, Yamamoto K, Suzuki S, et al:Strong interaction between the effects of alcohol consumption and smoking on oesophageal squamous cell carcinoma among individuals with ADH1B and/or ALDH2 risk alleles. Gut 59:1457-1464, 2010.
PubMed
15) Brooks PJ, Enoch MA, Goldman D, et al:The alcohol flushing response:an unrecognized risk factor for esophageal cancer from alcohol consumption, PLoS Med 6:e50, 2009.
PubMed
16) Wu C, Wang Z, Song X, et al:Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. Nat Genet 46:1001-1006, 2014.
 
17) Kuwano H, Yokobori T, Miyazaki T, et al:Field carcinogenesis and biological significance of the potential of the bystander effect:carcinogenesis, therapeutic response, and tissue regeneration. Surg Today 53:545-553, 2023.
PubMed
18) Yasuda M, Kuwano H, Watanabe M, et al:p53 expression in squamous dysplasia associated with carcinoma of the oesophagus:evidence for field carcinogenesis. Br J Cancer 83:1033-1038, 2000.
PubMed
19) Yokoyama A, Kakiuchi N, Yoshizato T, et al:Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 565:312-317, 2019.
PubMed
20) Killcoyne S, Gregson E, Wedge DC, et al:Genomic copy number predicts esophageal cancer years before transformation. Nat Med 26:1726-1732, 2020.
PubMed
21) Jammula S, Katz-Summercorn AC, Li X, et al:Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data. Gastroenterology 158:1682-1697.e1, 2020.
 
22) Bao C, Tourdot RW, Brunette GJ, et al:Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma, Nat Commun 14:6203, 2023.
 
23) Sun JM, Shen L, Shah MA, et al:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398:759-771, 2021.
PubMed
24) Hirata H, Niida A, Kakiuchi N, et al:The Evolving Genomic Landscape of Esophageal Squamous Cell Carcinoma Under Chemoradiotherapy. Cancer Res 81:4926-4938, 2021.
PubMed
25) Maron SB, Chatila W, Walch H, et al:Determinants of Survival with Combined HER2 and PD-1 Blockade in Metastatic Esophagogastric Cancer. Clin Cancer Res 29:3633-3640, 2023.
PubMed
26) Baselga J, Bhardwaj N, Cantley LC, et al:AACR Cancer Progress Report 2015. Clin Cancer Res 21:S1-S128, 2015.
PubMed
P.88 掲載の参考文献
1) Baba Y, Watanabe M, Baba H:Review of the alterations in DNA methylation in esophageal squamous cell carcinoma. Surg Today 43:1355-1364, 2013.
PubMed
2) Yu M, Hazelton WD, Luebeck GE, et al:Epigenetic Aging:More Than Just a Clock When It Comes to Cancer. Cancer Res 80:367-374, 2020.
PubMed
3) Kano M, Seki N, Kikkawa N, et al:miR-145, miR-133a and miR-133b:Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 127:2804-2814, 2010.
PubMed
4) Harada K, Baba Y, Ishimoto T, et al:The role of microRNA in esophageal squamous cell carcinoma. J Gastroenterol 51:520-530, 2016.
PubMed
5) Iswariya TG, Paital B, Padma PR, et al:microRNAs:Epigenetic players in cancer and aging. Front Biosci (Schol Ed) 11:29-55, 2019.
 
6) Horvath S, Raj K:DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet 19:371-384, 2018.
 
7) Yu M, Hazelton WD, Luebeck GE, et al:Epigenetic Aging:More Than Just a Clock When It Comes to Cancer. Cancer Res 80:367-374, 2020.
PubMed
8) Yang Z, Wong A, Kuh D, et al:Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol 17:205, 2016.
PubMed
9) Curtius K, Wong CJ, Hazelton WD, et al:A Molecular Clock Infers Heterogeneous Tissue Age Among Patients with Barrett's Esophagus. PLoS Comput Biol 12:e1004919, 2016.
 
10) Iwagami S, Baba Y, Watanabe M, et al:LINE-1 hypomethylation is associated with a poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. Ann Surg 257:449-455, 2013.
PubMed
11) Baba Y, Watanabe M, Murata A, et al:LINE-1 hypomethylation, DNA copy number alterations, and CDK6 amplification in esophageal squamous cell carcinoma. Clin Cancer Res 20:1114-1124, 2014.
PubMed
12) Schneider BJ, Shah MA, Klute K, et al:Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma:Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response. Clin Cancer Res 23:2673-2680, 2017.
PubMed
13) Zhang B, Long Q, Wu S, et al:KDM4 Orchestrates Epigenomic Remodeling of Senescent Cells and Potentiates the Senescence-Associated Secretory Phenotype. Nat Aging 1:454-472, 2021.
 
14) Tzao C, Tung HJ, Jin JS, et al:Prognostic significance of global histone modifications in resected squamous cell carcinoma of the esophagus. Mod Pathol 22:252-260, 2009.
PubMed
15) Hoshino I, Matsubara H, Hanari N, et al:Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells. Clin Cancer Res 11:7945-7952, 2005.
PubMed
P.95 掲載の参考文献
1) Sun JM, Shen L, Shah MA, et al:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398:759-771, 2021.
PubMed
2) Kojima T, Hara H, Tsuji A, et al:First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus 19:683-692, 2022.
 
3) Doki Y, Ajani JA, Kato K, et al:Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449-462, 2022.
PubMed
4) Kato K, Doki Y, Ogata T, et al:First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma:a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50). Esophagus 20:291-301, 2023.
 
5) 岡三喜男:読んで見てわかる免疫腫瘍学, p69-118, 中外医学社, 2017.
 
6) Mellman I, Chen DS, Powles T, et al:The cancer-immunity cycle:Indication, genotype, and immunotype. Immunity 56:2188-2205, 2023.
PubMed
7) Teng MW, Ngiow SF, Ribas A, et al:Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res 75:2139-2145, 2015.
 
8) Mimura K, Shiraishi K, Kobayashi M, et al:[The Mechanism of HLA Class I and PD-L1 Expression of Cancer Cells in Tumor Microenvironment]. Gan To Kagaku Ryoho 43:1027-1029, 2016.
 
9) Yoshimoto Y, Oike T, Okonogi N, et al:Carbon-ion beams induce production of an immune mediator protein, high mobility group box 1, at levels comparable with X-ray irradiation. J Radiat Res 56:509-514, 2015.
PubMed
10) Suzuki Y, Mimura K, Yoshimoto Y, et al:Immunogenic tumor cell death induced by chemoradiotherapy in patients with esophageal squamous cell carcinoma. Cancer Res 72:3967-3976, 2012.
PubMed
11) Yoshimoto Y, Suzuki Y, Mimura K, et al:Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model. PLoS One 9:e92572, 2014.
 
12) Sato H, Niimi A, Yasuhara T, et al:DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. Nat Commun 8:1751, 2017.
PubMed
13) Konno H, Yamauchi S, Berglund A, et al:Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037-2051, 2018.
PubMed
14) Nakajima S, Mimura K, Kaneta A, et al:Radiation-Induced Remodeling of the Tumor Microenvironment Through Tumor Cell-Intrinsic Expression of cGAS-STING in Esophageal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 115:957-971, 2023.
PubMed
P.100 掲載の参考文献
1) Baba Y, Iwatsuki M, Yoshida N, et al:Review of the gut microbiome and esophageal cancer:Pathogenesis and potential clinical implications. Ann Gastroenterol Surg 1:99-104, 2017.
PubMed
2) Yamamura K, Baba Y, Nakagawa S, et al:Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis. Clin Cancer Res 22:5574-5581, 2016.
PubMed
3) Nomoto D, Baba Y, Liu Y, et al:Fusobacterium nucleatum promotes esophageal squamous cell carcinoma progression via the NOD1/RIPK2/NF-κB pathway. Cancer Lett 530:59-67, 2022.
 
4) Baba Y, Hara Y, Toihata T, et al:Relationship between gut microbiome Fusobacterium nucleatum and LINE-1 methylation level in esophageal cancer. Esophagus 20:704-712, 2023.
PubMed
5) Yamamura K, Izumi D, Kandimalla R, et al:Intratumoral Fusobacterium Nucleatum Levels Predict Therapeutic Response to Neoadjuvant Chemotherapy in Esophageal Squamous Cell Carcinoma. Clin Cancer Res 25:6170-6179, 2019.
PubMed
6) Liu Y, Baba Y, Ishimoto T, et al:Fusobacterium nucleatum confers chemoresistance by modulating autophagy in oesophageal squamous cell carcinoma. Br J Cancer 124:963-974, 2021.
PubMed
7) Kosumi K, Baba Y, Yamamura K, et al:Intratumour Fusobacterium nucleatum and immune response to oesophageal cancer. Br J Cancer 128:1155-1165, 2023.
PubMed
8) Liu Y, Baba Y, Ishimoto T, et al:Progress in characterizing the linkage between Fusobacterium nucleatum and gastrointestinal cancer. J Gastroenterol 54:33-41, 2019.
PubMed

IV 食道腫瘍の病理

P.107 掲載の参考文献
1) Hamilton SR, Alaltonen LA (ed):World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System, IARCPress, Lyon, 2001.
 
2) 日本食道学会(編):臨床・病理食道癌取扱い規約 第10版, 金原出版, 2008.
 
3) Fujii S, Takubo K:Squamous dysplasia. In:WHO Classification of Tumours:Digestive System Tumours, 5th ed (ed by) WHO Classification of Tumours Editorial Board. IARC Press, Lyon, 2019.
 
4) 日本食道学会編:臨床・病理食道癌取扱い規約 第12版. 金原出版, 2022.
 
5) Arai T, Ono S, Takubo K:Squamous Neoplastic Precursor Lesions of the Esophagus. Gastroenterol Clin North Am 53:25-38, 2024.
PubMed
6) 根本哲生:食道上皮内腫瘍の病理学的検討-"食道上皮内腫瘍"とはどういうものか:病理医の立場から. 胃と腸 57:231-241, 2022.
 
7) 藤島史喜, 國吉真平, 佐藤聡子, ほか:食道上皮内腫瘍の病理学的検討. 胃と腸 57:243-249, 2022.
 
8) 新井冨生:食道上皮内腫瘍の臨床病理学的特徴. 胃と腸 57:1367-1372, 2022.
 
9) 小山恒男, 新井冨生, 眞能正幸, ほか:座談会 食道上皮内腫瘍を問う-アンケート集計を踏まえて. 胃と腸 57:310-344, 2022.
 
10) 竹内学, 高綱将史, 加藤卓, ほか:食道上皮内腫瘍の内視鏡的検討-ESD切除検体をもとに. 胃と腸 57:263-272, 2022.
 
11) 高橋亜紀子, 小山恒男, 塩澤哲, ほか:食道上皮内腫瘍の内視鏡的検討. 胃と腸 57:273-282, 2022.
 
12) 依光展和, 小田丈二, 入口陽介, ほか:経過観察中に癌化した食道上皮内腫瘍の1例. 胃と腸 57:283-288, 2022.
 
13) Arai T, Matsuda Y, Nishimura M, et al:Histopathological diagnoses of squamous intraepithelial neoplasia, carcinoma in situ and early invasive cancer of the oesophagus:the Japanese viewpoint. Diagn Histopathol 21:303-311, 2015.
 
14) Kobayashi M, Kawachi H, Takizawa T, et al:p53 Mutation analysis of low-grade dysplasia and highgrade dysplasia/carcinoma in situ of the esophagus using laser capture microdissection. Oncology 71:237-245, 2006.
PubMed
15) 河内洋:扁平上皮内腫瘍. 腫瘍病理鑑別診断アトラス 食道癌 第2版, p38-45, 文光堂, 2021.
 
P.113 掲載の参考文献
1) 天野祐二, 安積貴年, 坪井優, ほか:本邦におけるBarrett食道癌の疫学--現状と展望, 日消誌 112:219-231, 2015.
 
2) Imamura Y, Watanabe M, Toihata T, et al:Recent Incidence Trend of Surgically Resected Esophagogastric Junction Adenocarcinoma and Microsatellite Instability Status in Japanese Patients. Digestion 99:6-13, 2019.
PubMed
3) 日本食道学会(編):臨床・病理 食道癌取扱い規約 第12版, 金原出版, 2022.
 
4) Shaheen NJ, Falk GW, Iyer PG, et al:Diagnosis and Management of Barrett's Esophagus:An Updated ACG Guideline. Am J Gastroenterol 117:559-587, 2022.
 
5) Bhat S, Coleman HG, Yousef F, et al:Risk of Malignant Progression in Barrett's Esophagus Patients:Results from a Large Population-Based Study. J Natl Cancer Inst 103:1049-1057, 2011.
 
6) Takubo K, Aida J, Naomoto Y, et al:Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 40:65-74, 2009.
PubMed
7) 新井冨生:Barrett食道, 非腫瘍性疾患病理アトラス 消化管(九嶋亮治, 八尾隆史, 牛久哲男編), p38-46, 文光堂, 2023.
 
8) 河野辰幸, 神津照雄, 大原秀一, ほか:日本人のBarrett粘膜の頻度, 日本消化器内視鏡学会雑誌 47:951-961, 2005.
 
9) 向所賢一, 中山貴永, 九嶋亮治:Barrett食道腺癌の病理学的特徴 SSBE由来Barrett食道腺癌の特徴. 胃と腸 56:139-144, 2021.
 
10) 河内洋, 清水智樹, 高松学, ほか:表在型Barrett食道癌の病理学的特徴. 胃と腸 51:1259-1268, 2016.
 
11) Chandrasekar VT, Hamade N, Desai M, et al:Significantly lower annual rates of neoplastic progression in short- compared to long-segment non-dysplastic Barrett's esophagus:a systematic review and meta-analysis. Endoscopy 51:665-672, 2019.
 
12) Matsuhashi N, Sakai R, Ohata K, et al:Surveillance of patients with long-segment Barrett's esophagus;a multicenter prospective cohort study in Japan. J Gastroenterol Hepatol 32:409-414, 2017.
 
13) 小池智幸, 阿部靖彦, 飯島克則, ほか:Barrett食道癌の内視鏡診断-通常観察での拾い上げ診断のポイント 胃と腸 46:1800-1814, 2011.
 
14) Mather C, Koch L, Westerhoff M:The neoplastic esophagus. In:Fenoglio-Preiser's Gastrointestinal pathology, 4th edition (ed by Noffsinger AE), p96-135, Wolter Kluwer, Philadelphia, 2017.
 
15) 立石陽子:組織型と診断の実際主に食道胃接合部に発生する病変腺癌. 腫瘍病理鑑別診断アトラス 食道癌 第2版(大橋健一, 河内洋編), p117-123, 文光堂, 2021.
 
16) 小池智幸, 齊藤真弘, 大原祐樹, ほか:食道腫瘍性病変の内視鏡診断-Barrett食道癌の診断. 胃と腸 55:514-529, 2020.
 
17) Yamasaki A, Shimizu T, Kawachi H, et al:Endoscopic features of esophageal adenocarcinoma derived from short-segment versus long-segment Barrett's esophagus. J Gastroenterol Hepatol 35:211-217, 2020.
 
18) Matsui A, Kuribayashi Y, Nomura K, et al:Conventional White Light Endoscopic Features of Small Superficial Barrett's Esophageal Adenocarcinoma. Digestion 93:47-52, 2016.
 
19) 貝瀬満, 野田啓人, 樋口和寿, ほか:SSBE由来Barrett食道腺癌を効率よく拾い上げるコツ. 消化器内視鏡 33:1675-1684, 2021.
Medical*Online
20) Ikenoyama Y, Goda K, Fujisaki J, et al:A simpler diagnostic algorithm of the Japan Esophageal Society classification for Barrett's esophagus-related superficial neoplasia. Esophagus 21:22-30, 2024.
 
21) 河内洋, 中野薫, 藤崎順子:Barrett食道腺癌の病理学的特徴LSBEを中心に. 胃と腸 56:146-153, 2021.
 
22) 藤島史喜, 佐藤聡子, 國吉真平, ほか:食道病理をめぐるトピックス低異型度のBarrett食道腫瘍性病変の臨床病理学的検討. 胃と腸 57:1373-1379, 2022.
 
23) WHO Classification of Tumours Editorial Board (ed):WHO Classification of Tumours, Digestive System Tumours, 5th ed, IARC press, Lyon, 2019.
 
24) Skacel M, Petras RE, Rybicki LA, et al:p53 expression in low grade dysplasia in Barrett's esophagus;correlation with interobserver agreement and disease progression. Am J Gastroenterol 97:2508-2513, 2002.
 
25) Kaye PV, Haider SA, Ilyas M, et al:Barrett's dysplasia and the Vienna classification:reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry. Histopathology 54:699-712, 2009.
 
26) Faghani S, Codipilly DC, David Vogelsang, et al:Development of a deep learning model for the histologic diagnosis of dysplasia in Barrett's esophagus. Gastrointest Endosc 96:918-925.e3, 2022.
 
P.118 掲載の参考文献
1) 日本食道学会(編):臨床・病理 食道癌取扱い規約 第12版, 金原出版, 2022.
 
2) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
3) 大橋健一, 河内洋(編):鑑別診断アトラス 食道癌 第2版, 文光堂, 2021.
 
4) 河内洋, 佐藤由紀子, 中野薫:唾液腺型食道腫瘍の臨床病理学的特徴. 胃と腸 54:1419-1426, 2019.
 
5) WHO Classification of Tumours, Digestive System Tumours, 5th ed, IARC Press, Lyon, 2019.
 
6) 河内洋, 中野薫:食道:悪性黒色腫. 胃と腸 55:387-389, 2020.
 

V 食道癌「取扱い規約」の要点

P.126 掲載の参考文献
1) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
P.132 掲載の参考文献
1) Kanemura T, Miyata H, Takeoka T, et al:Significance of dissection in each regional lymph-node station of esophageal cancer based on efficacy index and recurrence patterns after curative esophagectomy. Esophagus 20:402-409, 2023.
PubMed
2) Taniyama Y, Murakami K, Yoshida N, et al:Evaluating the effect of Neoadjuvant chemotherapy for esophageal Cancer using the RECIST system with shorter-axis measurements:a retrospective multicenter study. BMC Cancer 21:1008, 2021.
PubMed
3) Yoshida N, Taniyama Y, Murakami K, et al:Novel Criterion Using Esophageal Major and Minor Axes is Useful to Evaluate the Therapeutic Effect and Prognosis After Neoadjuvant Chemotherapy Followed by Surgery in Locally Advanced Esophageal Cancer. Ann Surg Oncol 28:8474-8482, 2021.
PubMed
4) Murakami K, Yoshida N, Taniyama Y, et al:Maximum standardized uptake value change rate before and after neoadjuvant chemotherapy can predict early recurrence in patients with locally advanced esophageal cancer:a multi-institutional cohort study of 220 patients in Japan. Esophagus 19:205-213, 2022.
 
5) Kadota T, Abe S, Yoda Y, et al:Clinical outcomes according to the modified endoscopic criteria for neoadjuvant chemotherapy in resectable esophageal squamous cell carcinoma. Dig Endosc 32:337-345, 2020.
 
6) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
P.137 掲載の参考文献
1) Union for International Cancer Control. Oesophagus. In:TNM Classification of Malignant Tumours, 8 ed (ed by Brierley JD, Gospodarowicz MK, Wittekind C), Wiley Blackwell, 2016.
 
2) Skinner DB, Little AG, Ferguson MK, et al:Selection of operation for esophageal cancer based on staging. Ann Surg 204:391-401, 1986.
PubMed
3) Siewert JR, Fink U, Beckurts KT, et al:Surgery of squamous cell carcinoma of the esophagus. Ann Oncol 5(Suppl 3):1-7, 1994.
 
4) Matsubara T, Kaise T, Ishiguro M, et al:Better grading systems for evaluating the degree of lymph node invasion in cancer of the thoracic esophagus. Surg Today 24:500-505, 1994.
PubMed
5) Udagawa H, Ueno M, Shinohara H, et al:The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol 106:742-747, 2012.
PubMed
6) Udagawa H:Past, present, and future of three-field lymphadenectomy for thoracic esophageal cancer. Ann Gastroenterol Surg 4:324-330, 2020.
PubMed
7) Hulscher JB, van Sandick JW, de Boer AG, et al:Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662-1669, 2002.
PubMed
8) Rice TW, Blackstone EH, Rusch VW:A cancer staging primer:esophagus and esophagogastric junction. J Thorac Cardiovasc Surg 139:527-529, 2010.
PubMed
9) Mariette C, Piessen G:Oesophageal cancer:how radical should surgery be? Eur J Surg Oncol 38:210-213, 2012.
PubMed
10) Altorki NK, Skinner DB:Occult cervical nodal metastasis in esophageal cancer:preliminary results of three-field lymphadenectomy. J Thorac Cardiovasc Surg 113:540-544, 1997.
PubMed
11) Lerut T, Coosemans W, De Leyn P, et al:Reflections on three field lymphadenectomy in carcinoma of the esophagus and gastroesophageal junction. Hepatogastroenterology 46:717-725, 1999.
PubMed
12) Ye T, Sun Y, Zhang Y, et al:Three-field or two-field resection for thoracic esophageal cancer:a metaanalysis. Ann Thorac Surg 96:1933-1941, 2013.
PubMed
13) Ma GW, Situ DR, Ma QL, et al:Three-field vs two-field lymph node dissection for esophageal cancer:a meta-analysis. World J Gastroenterol 20:18022-18030, 2014.
PubMed
14) Bona D, Lombardo F, Matsushima K, et al:Three-field versus two-field lymphadenectomy for esophageal squamous cell carcinoma:A long-term survival meta-analysis. Surgery 171:940-947, 2022.
PubMed
15) Cui T, Zhang H, Yu T, et al:Pattern of Recurrence in 428 Patients With Thoracic Esophageal Squamous Cell Carcinoma After Radical Surgery and Its Implication in Postoperative Radiotherapeutic Clinical Target Volume. Front Oncol 11:652365, 2021.
 
P.143 掲載の参考文献
1) Union for International Cancer Control (UICC):TNM Classification of Malignant Tumours 8th edition, Wiley Blackwell, Oxford, 2017.
 
2) 日本食道学会(編):食道癌取り扱い規約 第12版, 金原出版, 2022.
 
3) American Joint Committee on Cancer:AJCC Cancer Staging Manual, 8th edition, Springer, Chicago, 2017.
 

VI 食道癌「診断治療ガイドライン」の要点

P.152 掲載の参考文献
1) 食道癌診療ガイドライン 2002年版(日本食道学会編)金原出版, 2002.
 
2) 食道癌診療ガイドライン 2007年版(日本食道学会編)金原出版, 2007.
 
3) 食道癌診療ガイドライン 2012年版(日本食道学会編)金原出版, 2012.
 
4) 食道癌診療ガイドライン 2017年版(日本食道学会編)金原出版, 2017.
 
5) 食道癌診療ガイドライン 2022年版(日本食道学会編)金原出版, 2022.
 
P.159 掲載の参考文献
1) 日本食道学会(編):食道癌診療ガイドライン 2017年版, 金原出版, 2017.
 
2) 日本食道学会(編):食道癌診療ガイドライン 2022年版, 金原出版, 2022.
 
3) Kato K, Ito Y, Nozaki I, et al:Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 161:1878-1886.e2, 2021.
 
4) Kelly RJ, Ajani JA, Kuzdzal J, et al:Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384:1191-1203, 2021.
PubMed
5) Ando N, Kato H, Igaki H, et al:A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68-74, 2012.
 
6) Kato K, Ito Y, Daiko H, et al:A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40(4 suppl):238, 2022.
 
7) Takeuchi H, Ito Y, Machida R, et al:A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys 114:454-462, 2022.
PubMed
8) Yokota T, Kato K, Hamamoto Y, et al:A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Ann Surg Oncol 27:460-467, 2020.
PubMed
9) Yokota T, Kato K, Hamamoto Y, et al:Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 115:1328-1334, 2016.
PubMed
10) Kato K, Cho BC, Takahashi M, et al:Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3):a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 20:1506-1517, 2019.
PubMed
11) Kojima T, Shah MA, Muro K, et al:Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. J Clin Oncol 38:4138-4148, 2020.
PubMed
12) Sun JM, Shen L, Shah MA, et al:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398:759-771, 2021.
PubMed
13) Doki Y, Ajani JA, Kato K, et al:Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449-462, 2022.
PubMed
P.168 掲載の参考文献
1) Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines:Clinical Practice Guidelines We Can Trust (ed by Graham R, Mancher M, Miller Wolman F, et al), p15:National Academy Press, Washington, D.C. 2011.
 
2) Minds 診療ガイドライン作成マニュアル編集委員(編):Minds診療ガイドライン作成マニュアル 2020 ver.3.0. 公益財団法人日本医療機能評価機構EBM医療情報部, 2021.
 
3) 吉田雅博:日本における診療ガイドライン作成の現況と課題. 化学療法研究所紀要 39:39-45, 2008.
Medical*Online
4) 日本医療機能評価機構:AGREE評価ツール. [https://minds.jcqhc.or.jp/methods/guidelineevaluation/agree/](2024/04/15確認)
 
5) AGREE Collaboration:Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines:the AGREE project. Qual Saf Health Care 12:18-23, 2003.
PubMed
6) Brouwers MC, Kho ME, Browman GP, et al:AGREE II:advancing guideline development, reporting and evaluation in health care. CMAJ 182:E839-E842, 2010.
PubMed
7) Brouwers MC, Kho ME, Browman GP, et al:Development of the AGREE II, part 1:performance, usefulness and areas for improvement. CMAJ 182:1045-1052, 2010.
PubMed
8) Brouwers MC, Kho ME, Browman GP, et al:Development of the AGREE II, part 2:assessment of validity of items and tools to support application. CMAJ 182:E472-E478, 2010.
PubMed
P.175 掲載の参考文献
1) Watanabe M, Tachimori Y, Oyama T, et al:Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus 18:1-24, 2021.
PubMed
2) Torre LA, Siegel RL, Ward EM, et al:Global Cancer Incidence and Mortality Rates and Trends-An Update. Cancer Epidemiol Biomarkers Prev 25:16-27, 2016.
PubMed
3) Turati F, Tramacere I, La Vecchia C, et al:A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma. Ann Oncol 24:609-617, 2013.
PubMed
4) Sharma P:Clinical practice. Barrett's esophagus. N Engl J Med 361:2548-2556, 2009.
 
5) 食道癌診療ガイドライン 2022年版(第5版)(日本食道学会編), 金原出版, 2022.
 
6) Ajani JA, D'Amico TA, Bentrem DJ, et al:Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21:393-422, 2023.
 
7) Obermannova R, Alsina M, Cervantes A, et al:Oesophageal cancer:ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 33:992-1004, 2022.
PubMed
8) Shaheen NJ, Falk GW, Iyer PG, et al:Diagnosis and Management of Barrett's Esophagus:An Updated ACG Guideline. Am J Gastroenterol 117:559-587, 2022.
 
9) Brierley JD, Gospodarowicz MK, Wittekind C (ed):TNM Classification of Malignant Tumours, 8th ed, Wily-Blackwell, 2017.
 

VII 食道癌の診断

P.182 掲載の参考文献
1) 食道癌診療ガイドライン 2022年版(日本食道学会編), 金原出版, 2022.
 
2) Hagi T, Makino T, Yamasaki M, et al:Pathological Regression of Lymph Nodes Better Predicts Long-term Survival in Esophageal Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery. Ann Surg 275:1121-1129, 2022.
PubMed
3) Takeuchi H, Kitagawa Y:Sentinel node navigation surgery in esophageal cancer. Ann Gastroenterol Surg 3:7-13, 2019.
PubMed
4) 有馬美和子, 多田正弘:超音波内視鏡検査. 日本臨牀 69(増刊号6:食道癌):169-173, 2011.
 
5) Ishihara R:Endoscopic Diagnosis and Treatment of Superficial Esophageal Squamous Cell Cancer:Present Status and Future Perspectives. Curr Oncol 29:534-543, 2022.
PubMed
6) Tachimori Y, Ozawa S, Numasaki H, et al:Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 13:110-137, 2016.
PubMed
7) Picus D, Balfe DM, Koehler RE, et al:Computed tomography in the staging of esophageal carcinoma. Radiology 146:433-438, 1983.
PubMed
8) 岡住慎一, 吉永有信, 首藤潔彦, ほか:MD-CTによる食道癌CRT後の質的効果判定-3D画像による手術シミュレーション. 手術 61:197-202, 2007.
 
9) Okazumi S, Ohira G, Hayano K, et al:Novel Advances in Qualitative Diagnostic Imaging for Decision Making in Multidisciplinary Treatment for Advanced Esophageal Cancer. J Clin Med 13:632, 2024.
PubMed
10) 矢野嘉政:食道癌における頸部・上縦隔リンパ節診断へのMRIの応用. 千葉医学雑誌 74:439-448, 1998.
 
11) 首藤潔彦, 岡住慎一, 松原久裕:癌の術式選択のための画像ナビゲーション食道癌の手術. 消化器外科 31:1339-1349, 2008.
 
12) Yamada H, Hosokawa M, Itoh K, et al:Diagnostic value of 18F-FDG PET/CT for lymph node metastasis of esophageal squamous cell carcinoma. Surg Today 44:1258-1265, 2014.
PubMed
13) Sakurada, Takahara T, Kwee TC, et al:Diagnostic performance of diffusion-weighted magnetic resonance imaging in esophageal cancer. Euro Radiol 19:1461-1469, 2009.
 
14) Sazuka T, Akai T, Uesato M, et al:Assessment for diagnosis of lymph node metastasis in esophageal cancer using endoscopic ultrasound elastography. Esophagus 13:254-263, 2016.
PubMed
15) Zhang ST, Wang SY, Zhang J, et al:Artificial intelligence-based computer-aided diagnosis system supports diagnosis of lymph node metastasis in esophageal squamous cell carcinoma:A multicenter study. Heliyon 9:e14030, 2023.
PubMed
P.189 掲載の参考文献
1) 今井裕:VII. 食道癌の診断食道造影検査. 日本臨牀 76(増刊:食道癌 第2版):158-163, 2018.
 
2) 今井裕, 桜田愛音, ほか:癌取扱い規約からみた悪性腫瘍の病理診断と画像診断. 消化器癌;食道. 臨床放射線 50(増刊):11, 2005.
 
3) 今井裕, 那須政司, 幕内博康, ほか:特殊組織型の食道癌;X線の立場から. 胃と腸 40:301-309, 2005.
 
4) Barrett NR:Chronic peptic ulcer of the esophagus and esophagitis. Br J Surg 38:175-182, 1950.
PubMed
5) Levine MS, Kressel HY, Caroline DF, et al:Barrett esophagus:reticular pattern of the mucosa. Radiology 147:663-667, 1983.
PubMed
6) 銭谷明, 石岡知憲, 正宗研, ほか:Barrett食道に発生した食道表在腺癌の1例. 胃と腸 30:1445-1450, 1995.
 
7) 今井裕, 川田秀一, 幕内博康, ほか:Barrett食道癌のX線診断. 胃と腸 39:1234-1242, 2004.
 
P.196 掲載の参考文献
1) 武藤学, ほか:咽頭・食道 1 観察法. 日本消化器内視鏡学会(監):消化器内視鏡ハンドブック, 改訂第2版, p166-178, 日本メディカルセンター, 2017.
 
2) 藤原純子, 門馬久美子:NBI併用内視鏡による食道癌スクリーニング. 消化器内視鏡 53(Suppl 2):2390, 2011.
 
3) 高橋亜紀子, ほか:食道表在癌のスクリーニング 拡大内視鏡. 胃と腸 46:611-620, 2011.
 
4) 日本食道学会(編):臨床・病理 食道癌取り扱い規約, 第12版, 金原出版, 2022.
 
5) 門馬久美子, 藤原純子:内視鏡検査 扁平上皮癌(通常観察). 日本臨牀(増刊号6) 69:143-149, 2011.
Medical*Online
6) Muto M, Minashi K, Yano T, et al:Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging:a multicenter randomized controlled trial. J Clin Oncol 28:1566-1572, 2010.
PubMed
7) Nagami Y, Tominaga K, Machida H, et al:Usefulness of non-magnifying narrow-band imaging in screening of early esophageal squamous cell carcinoma:a prospective comparative study using propensity score matching. Am J Gastroenterol 109:845-854, 2014.
PubMed
8) Oyama T, Momma K:A new classification of magnified endoscopy for superficial esophageal squamous cell carcinoma. Esophagus 8:247-251, 2011.
 
9) 友利彰寿, 小山恒男, 高橋亜紀子, ほか:隆起型食道扁平上皮癌の深達度診断-拡大内視鏡を中心に. 胃と腸 48:337-345, 2013.
 
10) Katada C, Yokoyama T, Yano T, et al:Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. Gastroenterology 151:860-869.e7, 2016.
 
11) Shimizu Y, Omori T, Yokoyama A, et al:Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining:high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol 23:546-550, 2008.
PubMed
12) Makuuchi H:Endoscopic mucosal resection for early esophageal cancer:Indications and techniques. Dig Endosc 8:175-179, 1996.
 
13) 日本食道癌学会(編):食道癌診療ガイドライン, 2022年版, 金原出版, 2022.
 
14) Minashi K, Nihei K, Mizusawa J, et al:Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 157:382-390.e3, 2019.
 
P.202 掲載の参考文献
1) Yokoyama A, Watanabe H, Fukuda H, et al:Multiple cancers associated with esophageal and oropharyngolaryngeal squamous cell carcinoma and the aldehyde dehydrogenase-2 genotype in male Japanese drinkers. Cancer Epidemiol Biomarkers Prev 11:895-900, 2002.
PubMed
2) Yokoyama A, Omori T, Yokoyama T:Alcohol and aldehyde dehydrogenase polymorphisms and a new strategy for prevention and screening for cancer in the upper aerodigestive tract in East Asians. Keio J Med 59:115-130, 2010.
 
3) Shigaki H, Imamura Y, Mine S, et al:Clinicopathological features of esophageal squamous cell carcinoma in neversmoker-never drinkers.Dis of Esophagus 30:1-7, 2017.
 
4) Yokoyama A, Mizukami T, Omori T, et al:Melanosis and squamous cell neoplasms of the upper aerodigestive tract in Japanese alcoholic men. Cancer Sci 97:905-911, 2006.
PubMed
5) 川田研郎, 永井鑑, 中島康晃, ほか:"経鼻内視鏡ならでは"の観察法-中咽頭反転法とValsalva法 消化器内視鏡 24:1406-1409, 2012.
Medical*Online
6) Inoue H, Fujiyoshi Y, Abad MRA, et al:A novel endoscopic assessment of the gastroesophageal junction for the prediction of gastroesophageal reflux disease:a pilot study. Endosc Int Open 7:E1468-E1473, 2019.
PubMed
7) Kishino T, Kitamura Y, Shimokobe H:Usefulness of the "continuous insufflation method" for observing the cervical esophagus. Dis Endosc 30:526, 2018.
 
8) Gono K, Yamazaki K, Doguchi N, et al:Endoscopic observation of tissue by narrow band illumination. Optical Review 10:211-215, 2003.
 
9) Muto M, Nakane M, Katada C, et al:Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer 101:1375-1381, 2004.
PubMed
10) Ono S, Kawada K, Dohi O, et al:Linked Color Imaging Focused on Neoplasm Detection in the Upper Gastrointestinal Tract:A Randomized Trial. Ann Intern Med 174:18-24, 2021.
PubMed
11) Haruma K, Kato M, Kawada K, et al:Diagnostic ability of linked color imaging in ultraslim endoscopy to identify neoplastic lesions in the upper gastrointestinal tract. Endosc Int Open 10:E88-E95, 2022.
PubMed
12) Ogata Y, Hatta W, Koike T, et al:Blue light imaging and linked color imaging as a screening mode for esophageal squamous cell carcinoma in high-risk patients:Multicenter randomized trial. Dig Endosc 35:835-844, 2023.
PubMed
13) Inoue H, Honda T, Nagai K, et al:Ultra-high magnification endoscopic observation of carcinoma in situ of the esophagus. Dig Endosc 9:16-18, 1997.
 
14) Arima M, Tada M, Arima H:Evaluation of microvascular patterns of superficial esophageal cancers by magnifying endoscopy. Esophagus 2:191-197, 2005.
 
15) Oyama T, Inoue H, Arima M, et al:Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology:magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 14:105-112, 2017.
PubMed
P.207 掲載の参考文献
1) 門馬久美子, 藤原純子:食道癌の診断 内視鏡検査 扁平上皮癌(通常観察). 日本臨牀 69(増刊:食道癌):143-149, 2011.
 
2) Shimizu Y, Omori T, Yokoyama A, et al:Endoscopic diagnosis of early squamous neoplasia of the esophagus with iodine staining:high-grade intra-epithelial neoplasia turns pink within a few minutes. J Gastroenterol Hepatol 23:546-550, 2008.
PubMed
3) Muto M, Minashi K, Yano T, et al:Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging:a multicenter randomized controlled trial. J Clin Oncol 28:1566-1572, 2010.
PubMed
4) Goda K, Tajiri H, Ikegami M, et al:Magnifying endoscopy with narrow band imaging for predicting the invasion depth of superficial esophageal squamous cell carcinoma. Dis Esophagus 22:453-460, 2009.
PubMed
5) 郷田憲一:食道表在癌の内視鏡診断 扁平上皮癌・Barrett腺癌. 消化器内科 2:84-91, 2020.
 
6) 井上晴洋, 加賀まこと, 菅谷聡, ほか:こだわりの境界診断とESD-ピンクカラーサインとシルバーメタリックサイン-. 消化器内視鏡 18:171-178, 2006.
 
7) Goda K, Dobashi A, Yoshimura N, et al:Dual-focus versus conventional magnification endoscopy for the diagnosis of superficial squamous neoplasms in the pharynx and esophagus:a randomized trial. Endoscopy 48:321-329, 2016.
PubMed
8) Yoshida Y, Goda K, Tajiri H, et al:Assessment of novel endoscopic techniques for visualizing superficial esophageal squamous cell carcinoma:autofluorescence and narrow-band imaging. Dis Esophagus 22:439-446, 2009.
PubMed
9) Inoue H, Honda T, Nagai K, et al:Ultra-high magnification endoscopic observation of carcinoma in situ of the esophagus. Dig Endosc 9:16-18, 1997.
 
10) Arima M, Tada M, Arima H:Evaluation of microvascular patterns of superficial esophageal cancers by magnifying endoscopy. Esophagus 2:191-197, 2005.
 
11) Oyama T, Inoue H, Arima M, et al:Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology:magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 14:105-112, 2017.
PubMed
12) Goda K, Dobashi A, Yoshimura N, et al:Narrow-Band Imaging Magnifying Endoscopy versus Lugol Chromoendoscopy with Pink-Color Sign Assessment in the Diagnosis of Superficial Esophageal Squamous Neoplasms:A Randomised Noninferiority Trial. Gastroenterol Res Pract 2015:639462, 2015.
PubMed
13) Takahashi M, Shimizu Y, Ono M, et al:Endoscopic diagnosis of early neoplasia of the esophagus with narrow band imaging:correlations among background coloration and iodine staining findings. J Gastroenterol Hepatol 29:762-768, 2014.
PubMed
14) Goda K, Irisawa A:Japan Esophageal Society classification for predicting the invasion depth of superficial esophageal squamous cell carcinoma:Should it be modified now? Dig Endosc 32:37-38, 2020.
PubMed
15) Fukuda H, Ishihara R, Kato Y, et al:Comparison of performances of artificial intelligence versus expert endoscopists for real-time assisted diagnosis of esophageal squamous cell carcinoma (with video). Gastrointest Endosc 92:848-855, 2020.
PubMed
P.216 掲載の参考文献
1) Nishi T, Makuuchi H, Ozawa S, et al:The Present Status and Future of Barrett's Esophageal Adenocarcinoma in Japan. Digestion 99:185-190, 2019.
 
2) 食道癌取扱い規約 第12版(日本食道学会編), 2022年.
 
3) Haggitt RC, Dean PJ:Adenocarcinoma in Barrett's epithelium. In:Barrett' s Esophagus:Pathophysiology, Diagnosis and Management. (ed by Spechler SJ, Goyal RK), p153-166, Elsevier Science Publishing, New York, 1985.
 
4) Chandrasoma P, Wijetunge S, DeMeester S, et al:Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 36:1-7, 2012.
PubMed
5) Takubo K, Aida J, Naomoto Y, et al:Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum Pathol 40:65-74, 2009.
PubMed
6) Sharma P, Dent J, Armstrong D, et al:The development and validation of an endoscopic grading system for Barrett's esophagus:the Prague C & M criteria. Gastroenterology 131:1392-1399, 2006.
 
7) Krishnamoorthi R, Singh S, Ragunathan K, et al:Factors Associated With Progression of Barrett's Esophagus:A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 16:1046-1055.e8, 2018.
 
8) Matsui A, Kuribayashi Y, Nomura K, et al:Conventional White Light Endoscopic Features of Small Superficial Barrett's Esophageal Adenocarcinoma. Digestion 93:47-52, 2016.
 
9) Sharma P, Bergman JJ, Goda K, et al:Development and Validation of a Classification System to Identify High-Grade Dysplasia and Esophageal Adenocarcinoma in Barrett's Esophagus Using Narrow-Band Imaging. Gastroenterology 150:591-598, 2016.
 
10) Goda K, Fujisaki J, Ishihara R, et al:Newly developed magnifying endoscopic classification of the Japan Esophageal Society to identify superficial Barrett's esophagus-related neoplasms. Esophagus 15:153-159, 2018.
 
11) Muto M, Yao K, Kaise M, et al:Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G). Dig Endosc 28:379-393, 2016.
PubMed
12) Ishihara R, Oyama T, Abe S, et al:Risk of metastasis in adenocarcinoma of the esophagus:a multicenter retrospective study in a Japanese population. J Gastroenterol 52:800-808, 2017.
 
P.221 掲載の参考文献
1) Yamashina T, Ishihara R, Nagai K, et al:Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol 108:544-551, 2013.
PubMed
2) Kitagawa Y, Uno T, Oyama T, et al:Esophageal cancer practice guidelines 2017 edited by the Japan esophageal society:part 2. Esophagus 16:25-43, 2019.
PubMed
3) Oyama T, Inoue H, Arima M, et al:Prediction of the invasion depth of superficial squamous cell carcinoma based on microvessel morphology:magnifying endoscopic classification of the Japan Esophageal Society. Esophagus 14:105-112, 2017.
PubMed
4) Ishihara R, Arima M, Iizuka T, et al:Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 32:452-493, 2020.
PubMed
5) Ishihara R, Matsuura N, Hanaoka N, et al:Endoscopic imaging modalities for diagnosing invasion depth of superficial esophageal squamous cell carcinoma:a systematic review and meta-analysis. BMC Gastroenterol 17:24, 2017.
PubMed
6) Thosani N, Singh H, Kapadia A, et al:Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers:a systematic review and meta-analysis. Gastrointest Endosc 75:242-253, 2012.
PubMed
7) Park CH, Yang DH, Kim JW, et al:Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer. Clin Endosc 53:142-166, 2020.
PubMed
8) ASGE Standards of Practice Committee;Evans JA, Early DS, Chandrasekhara V, et al:The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 77:328-334, 2013.
 
9) Othman MO, Lee JH, Wang K:Clinical Practice Update on the Utility of Endoscopic Submucosal Dissection in T1b Esophageal Cancer:Expert Review. Clin Gastroenterol Hepatol 17:2161-2166, 2019.
PubMed
10) Pimentel-Nunes P, Dinis-Ribeiro M, Ponchon T, et al:Endoscopic submucosal dissection:European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 47:829-854, 2015.
PubMed
11) Ajani JA, D'Amico TA, Bentrem DJ, et al:Esophageal and esophagogastric junction cancers, version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 17:855-883. 2019.
 
12) Nakamura J, Manabe N, Yamatsuji T, et al:Subjective factors affecting prognosis of 469 patients with esophageal squamous cell carcinoma:a retrospective cohort study of endoscopic screening. BMC Gastroenterol 22:319, 2022.
PubMed
13) Inoue T, Ishihara R, Shibata T, et al:Endoscopic imaging modalities for diagnosing the invasion depth of superficial esophageal squamous cell carcinoma:a systematic review. Esophagus 19:375-383, 2022.
 
14) Goda K, Tajiri H, Ikegami M, et al:Magnifying endoscopy with narrow band imaging for predicting the invasion depth of superficial esophageal squamous cell carcinoma. Dis Esophagus 22:453-460, 2009.
PubMed
15) Ishihara R, Mizusawa J, Kushima R, et al:Assessment of the diagnostic performance of endoscopic ultrasonography after conventional endoscopy for the evaluation of esophageal squamous cell carcinoma invasion depth. JAMA New Open 4:e2125317, 2021.
 
P.227 掲載の参考文献
1) 食道癌取扱い規約, 第12版(日本食道学会編), p84-87, 金原出版, 2022.
 
2) Hong SJ, Kim TJ, Nam KB, et al:New TNM staging system for esophageal cancer:what chest radiologists need to know. Radiographics 34:1722-1740, 2014.
PubMed
3) Picus D, Balfe DM, Koehler RE, et al:Computed tomography in the staging of esophageal carcinoma. Radiology 146:433-438, 1983.
PubMed
4) 奥田逸子, 小久保宇, 宇田川晴司, ほか:食道癌の縦隔リンパ節転移のCT診断. 日本医放会誌 57:391-394, 1997.
 
5) Funai T, Osugi H, Higashino M, et al:Estimation of lymph node metastasis by size in patients with intrathoracic oesophageal cancer. Br J Surg 87:1234-1239, 2000.
PubMed
6) Foley KG, Christian A, Fielding P, et al:Accuracy of contemporary oesophageal cancer lymph node staging with radiological-pathological correlation. Clin Radiol 72:693.e1-693.e7, 2017.
 
7) Kato H, Miyazaki T, Nakajima M, et al:The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103:148-156, 2005.
PubMed
8) Karashima R, Watanabe M, Imamura Y, et al:Advantages of FDG-PET/CT over CT alone in the preoperative assessment of lymph node metastasis in patients with esophageal cancer. Surg Today 45:471-477, 2015.
PubMed
9) Okada M, Murakami T, Kumano S, et al:Integrated FDG-PET/CT compared with intravenous contrast-enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer. Ann Nucl Med 23:73-80, 2009.
PubMed
10) Liu J, Wang Z, Shao H, et al:Improving CT detection sensitivity for nodal metastases in oesophageal cancer with combination of smaller size and lymph node axial ratio. Eur Radiol 28:188-195, 2018.
PubMed
11) Tan R, Yao SZ, Huang ZQ, et al:Combination of FDG PET/CT and contrast-enhanced MSCT in detecting lymph node metastasis of esophageal cancer. Asian Pac J Cancer Prev 15:7719-7724, 2014.
PubMed
12) Winiker M, Mantziari S, Figueiredo SG, et al:Accuracy of preoperative staging for a priori resectable esophageal cancer. Dis Esophagus 31:1-6, 2018.
PubMed
13) 首藤潔彦, 岡住慎一, 松原久裕:癌の術式選択のための画像ナビゲーション食道癌の手術. 消化器外科 31:1339-1349, 2008.
 
14) Hu Y, Xie C, Yang H, et al:Computed tomography-based deep-learning prediction of neoadjuvant chemoradiotherapy treatment response in esophageal squamous cell carcinoma. Radiother Oncol 154:6-13, 2021.
 
15) Wu L, Yang X, Cao W, et al:Multiple level CT radiomics features preoperatively predict lymph node metastasis in esophageal cancer:A multicenter retrospective study. Front Oncol 9:1548, 2020.
 
P.233 掲載の参考文献
1) Luo LN, He LJ, Gao XY, et al:Endoscopic Ultrasound for Preoperative Esophageal Squamous Cell Carcinoma:a Meta-Analysis. PLoS One 11:e0158373, 2016.
PubMed
2) Riddell AM, Allum WH, Thompson JN, et al:The appearances of oesophageal carcinoma demonstrated on high-resolution, T2-weighted MRI, with histopathological correlation. Eur Radiol 17:391-399, 2007.
PubMed
3) Lee SL, Yadav P, Starekova J, et al:Diagnostic Performance of MRI for Esophageal Carcinoma:A Systematic Review and Meta-Analysis. Radiology 299:583-594, 2021.
PubMed
4) Pellat A, Dohan A, Soyer P, et al:The Role of Magnetic Resonance Imaging in the Management of Esophageal Cancer. Cancers (Basel) 14:1141, 2022.
PubMed
5) Koyama T, Umeoka S, Saga T, et al:Evaluation of esophageal peristalsis in patients with esophageal tumors:initial experience with cine MR imaging. Magn Reson Med Sci 4:109-114, 2005.
PubMed
6) Haefliger L, Jreige M, Du Pasquier C, et al:Esophageal cancer T-staging on MRI:A preliminary study using cine and static MR sequences. Eur J Radiol 166:111001, 2023.
PubMed
7) Shuto K, Kono T, Shiratori T, et al:Diagnostic performance of diffusion-weighted magnetic resonance imaging in assessing lymph node metastasis of esophageal cancer compared with PET. Esophagus 17:239-249, 2020.
PubMed
8) Hu J, Zhu D, Yang Y:Diagnostic value of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for preoperative lymph node metastasis of esophageal cancer:A metaanalysis. Medicine (Baltimore) 97:e13722, 2018.
 
9) Yamamoto M, Yoshida M, Furuse J, et al:Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. J Hepatobiliary Pancreat Sci 28:1-25, 2021.
PubMed
10) Hayano K, Ohira G, Hirata A, et al:Imaging biomarkers for the treatment of esophageal cancer. World J Gastroenterol 25:3021-3029, 2019.
PubMed
11) Lei J, Han Q, Zhu S, et al:Assessment of esophageal carcinoma undergoing concurrent chemoradiotherapy with quantitative dynamic contrast-enhanced magnetic resonance imaging. Oncol Lett 10:3607-3612, 2015.
PubMed
12) Sun NN, Liu C, Ge XL, et al:Dynamic contrast-enhanced MRI for advanced esophageal cancer response assessment after concurrent chemoradiotherapy. Diagn Interv Radiol 24:195-202, 2018.
PubMed
13) Cheng B, Yu J:Predictive value of diffusion-weighted MR imaging in early response to chemoradiotherapy of esophageal cancer:a meta-analysis. Dis Esophagus 32:doy065, 2019.
 
14) Hirata A, Hayano K, Ohira G, et al:Volumetric histogram analysis of apparent diffusion coefficient for predicting pathological complete response and survival in esophageal cancer patients treated with chemoradiotherapy. Am J Surg 219:1024-1029, 2020.
PubMed
15) Mizumachi R, Hayano K, Hirata A, et al:Development of imaging biomarker for esophageal cancer using intravoxel incoherent motion MRI. Esophagus 18:844-850, 2021.
PubMed
P.238 掲載の参考文献
1) 加藤広行, 百目木泰, 菅原学:PET検査. 日本臨牀 69:182-189, 2011.
Medical*Online
2) FDG PET, PET/CT診療ガイドライン 2020, 日本核医学会, 2020年8月.
 
3) 白石治, 加藤寛章, 岩間密, ほか:PET. 日本臨牀 76(増刊号8:食道癌第2版):206-212, 2018.
 
4) 加藤広行, 深井康幸, 桑野博行:PETと消化器疾患 食道癌におけるFDG-PET検査. GI Research 14:437-444, 2006.
 
5) Kato H, Kuwano H, Nakajima M, et al:Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94:921-928, 2002.
PubMed
6) Higuchi I, Yasuda T, Yano M, et al:Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 136:205-212.e2123, 2008.
 
7) van Vliet EP, Heijenbrok-Kal MH, Hunink MG, et al:Staging investigations for oesophageal cancer:a meta-analysis. Br J Cancer 98:547-557, 2008.
PubMed
8) Jayaprakasam VS, Yeh R, Ku GY, et al:Role of Imaging in Esophageal Cancer Management in 2020:Update for Radiologists. AJR Am J Roentgenol 215:1072-1084, 2020.
PubMed
9) Yanagawa M, Tatsumi M, Miyata H, et al:Evaluation of response to neoadjuvant chemotherapy for esophageal cancer:PET response criteria in solid tumors versus response evaluation criteria in solid tumors. J Nucl Med 53:872-880, 2012.
PubMed
10) Sharma P, Siddiqui BA, Anandhan S, et al:The Next Decade of Immune Checkpoint Therapy. Cancer Discov 11:838-857, 2021.
PubMed
11) Wargo JA, Reddy SM, Reuben A, et al:Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol 41:23-31, 2016.
PubMed
12) Kuriyama K, Higuchi T, Yokobori T, et al:Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma. Cancer Sci 111:1969-1978, 2020.
PubMed
13) Yendamuri S, Swisher SG, Correa AM, et al:Esophageal tumor length is independently associated with long-term survival. Cancer 115:508-516, 2009.
PubMed
14) Foley KG, Fielding P, Lewis WG, et al:Prognostic significance of novel 18F-FDG PET/CT defined tumour variables in patients with oesophageal cancer. Eur J Radiol 83:1069-1073, 2014.
PubMed
15) Makino T, Yamasaki M, Tanaka K, et al:Metabolic Tumor Volume Change Predicts Long-term Survival and Histological Response to Preoperative Chemotherapy in Locally Advanced Esophageal Cancer. Ann Surg 270:1090-1095, 2019.
PubMed
P.243 掲載の参考文献
1) 分子腫瘍マーカー診療ガイドライン 第2版(日本分子腫瘍マーカー研究会編), p68-73, 金原出版, 2021.
 
2) Shimada H, Noie T, Ohashi M, et al:Clinical significance of serum tumor markers for gastric cancer:a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 17:26-33, 2014.
 
3) Shimada H, Nabeya Y, Okazumi S, et al:Prediction of survival with squamous cell carcinoma antigen in patients with resectable esophageal squamous cell carcinoma. Surgery 133:486-494, 2003.
PubMed
4) Shimada H, Takeda A, Arima M, et al:Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677-1683, 2000.
PubMed
5) Takashi S, Satoshi Y, Akihiko O, et al:Clinical impact of preoperative serum p53 antibody titers in 1487 patients with surgically treated esophageal squamous cell carcinoma:a multi-institutional study. Esophagus 18:65-71, 2021.
PubMed
6) Shimada H, Shiratori T, Takeda A, et al:Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg 33:272-277, 2009.
PubMed
7) Shimada H, et al:Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors:a multi-institutional analysis by the Japan p53 Antibody Research Group. Cancer 97:682-689, 2003.
 
8) Suzuki T, et al:Prognostic impact of carcinoembryonic antigen in 1822 surgically treated esophageal squamous cell carcinoma:multi-institutional study of the Japan Esophageal Society. Dis Esophagus 35:doac029, 2022.
PubMed
9) Ishioka N, Suzuki T, Yajima S, et al:Prognostic Impact of Pretreatment Serum CYFRA Status in 1047 Patients with Esophageal Squamous Cell Carcinoma Who Underwent Radical Resection:A Japan Esophageal Society Promotion Research. Ann Thorac Cardiovasc Surg 28:163-170, 2022.
PubMed
10) Shimada H, Nabeya Y, Okazumi S, et al:Prognostic value of preoperative serum immunosuppressive acidic protein in patients with esophageal squamous cell carcinoma. Dis Esophagus 16:102-106, 2003.
PubMed
11) Shimada H, Nabeya Y, Okazumi S, et al:Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 83:248-252, 2003.
 
12) Shimada H, Oohira G, Okazumi S, et al:Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 198:737-741, 2004.
PubMed
13) Shimada H, Takeda A, Nabeya Y, et al:Clinical significance of serum vascular endothelial growth factor in esophageal squamous cell carcinoma. Cancer 92:663-669, 2001.
PubMed
14) Shimada H, Takeda A, Shiratori T, et al:Prognostic significance of serum thymidine phosphorylase concentration in esophageal squamous cell carcinoma. Cancer 94:1947-1954, 2002.
PubMed
15) Shimada H, Nagata M, Cho A, et al:Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma:report of a case. Surg Today 44:1957-1961, 2014.
PubMed
P.249 掲載の参考文献
1) Miyata H, Yamasaki M, Kurokawa Y, et al:Survival factors in patients with recurrence after curative resection of esophageal squamous cell carcinomas. Ann Surg Oncol 18:3353-3361, 2011.
PubMed
2) Shimada H, Takeda A, Arima M, et al:Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer 89:1677-1683, 2000.
PubMed
3) Wang M, Liu F, Pan Y, et al:Tumor-associated autoantibodies in ESCC screening:Detecting prevalent early-stage malignancy or predicting future cancer risk? EBioMedicine 73:103674, 2021.
PubMed
4) Darga EP, Dolce EM, Fang F, et al:PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer. PLoS One 16:e0260124, 2021.
PubMed
5) Ishiguro Y, Sakihama H, Yoshida T, et al:Prognostic Significance of Circulating Tumor Cells with Mesenchymal Phenotypes in Patients with Gastric Cancer:A Prospective Study. Ann Surg Oncol 28:1178-1186, 2021.
 
6) Matsushita D, Arigami T, Okubo K, et al:The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer:A Systematic Review and Meta-Analysis. Cancers (Basel) 12:3070, 2020.
PubMed
7) Min J, Zhou H, Jiang S, et al:A Review of Circulating Tumor DNA in the Diagnosis and Monitoring of Esophageal Cancer. Med Sci Monit 28:e934106, 2022.
 
8) Vogelstein B, Kinzler KW:Digital PCR. Proc Natl Acad Sci U S A 96:9236-9241, 1999.
PubMed
9) Bettegowda C, Sausen M, Leary RJ, et al:Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6:224ra24, 2014.
PubMed
10) Dasari A, Morris VK, Allegra CJ, et al:ctDNA applications and integration in colorectal cancer:an NCI Colon and Rectal-Anal Task Forces whitepaper. Nat Rev Clin Oncol 17:757-770, 2020.
PubMed
11) Taniguchi H, Nakamura Y, Kotani D, et al:CIRCULATE-Japan:Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci 112:2915-2920, 2021.
PubMed
12) Azad TD, Chaudhuri AA, Fang P, et al:Circulating Tumor DNA Analysis for Detection of Minimal Residual Disease After Chemoradiotherapy for Localized Esophageal Cancer. Gastroenterology 158:494-505.e6, 2020.
 
13) Ococks E, Frankell AM, Masque Soler N, et al:Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling. Ann Oncol 32:522-532, 2021.
PubMed
14) Iwaya T, Endo F, Takahashi F, et al:Frequent Tumor Burden Monitoring of Esophageal Squamous Cell Carcinoma With Circulating Tumor DNA Using Individually Designed Digital Polymerase Chain Reaction. Gastroenterology 160:463-465.e4, 2021.
 
15) Kishida T, Kanda M, Sato Y, et al:Risk Stratification by Tissue GAD1 Expression Level in Curatively Resected Esophageal Squamous Cell Carcinoma. Cancer Genomics Proteomics 20:617-625, 2023.
PubMed

VIII 食道癌の治療

P.258 掲載の参考文献
1) 加藤広行, ほか:頸部進行食道癌に対する手術. 消化器外科 31:1611-1621, 2008.
 
2) 中島政信, 加藤広行, 百目木泰:頸部食道癌. 臨床外科 69:88-90, 2014.
 
3) 宇田川晴司, ほか:根治手術 頸部食道癌, 臨床食道学(小澤壮治, 木下芳一編), 南江堂, 2015.
 
4) 食道癌診療ガイドライン 2022年版(日本食道学会編), 金原出版, 2022.
 
5) 食道癌診療ガイドライン 2017年版(日本食道学会編), 金原出版, 2017.
 
6) 白石治, 錦耕平, 岩間密, ほか:咽喉頭・頸部食道癌の治療戦略 導入化学放射線療法と術式工夫による喉頭温存を重視した集学的治療戦略. 日気管食道会報 65:144-147, 2014.
 
7) 安田卓司, 今本治彦, 土岐裕一郎, ほか:下咽頭・頸部食道癌の治療戦略 頸部食道癌に対する治療戦略-更なる根治性と機能性の向上を目指して. 日気管食道会報 59:99-102, 2008.
 
8) 中島康晃, 川田研郎, 東海林裕, ほか:頸部食道癌に対する手術治療-喉頭温存を目指した手術戦略. 日気管食道会報 65:447-456, 2014.
 
9) Mayanagi S, Onitsuka T, Nakagawa M, et al:The use of short segment free jejunal transfer as salvage surgery for cervical esophageal and hypopharyngeal cancer. World J Surg 38:144-149, 2014.
PubMed
10) Ullah R, Bailie N, Kinsella J, et al:Pharyngo-laryngo-oesophagectomy and gastric pull-up for postcricoid and cervical oesophageal squamous cell carcinoma. J Laryngol Otol 116:826-830, 2002.
PubMed
11) Yamasaki M, Miyata H, Miyazaki Y, et al:Pattern of Lymphatic Spread of Esophageal Cancer at the Cervicothoracic Junction Based on the Tumor Location:Surgical Treatment of Esophageal Squamous Cell Carcinoma of the Cervicothoracic Junction. Ann Surg Oncol 22(Suppl 3):S750-S757, 2015.
 
12) Martins AS:Neck and mediastinal node dissection in pharyngolaryngoesophageal tumors. Head Neck 23:772-779, 2001.
PubMed
13) Fujita H, Kakegawa T, Yamana H, et al:Total esophagectomy versus proximal esophagectomy for esophageal cancer at the cervicothoracic junction. World J Surg 23:486-491, 1999.
PubMed
14) Kato H, Kitagawa Y, Kuwano H, et al:Neo-adjuvant therapy or definitive chemoradiotherapy can improve laryngeal preservation rates in patients with cervical esophageal cancer. A Japanese nationwide survey, Esophagus 13:276-282, 2016.
 
15) Grillo HC:Circumferential resection and reconstruction of the mediastinal and cervical trachea. Ann Surg 162:374-388, 1965.
PubMed
P.265 掲載の参考文献
1) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
2) 特定非営利活動法人 日本食道学会(編):食道癌診療ガイドライン 2022年版, 金原出版, 2022.
 
3) Kato K, Ito Y, Nozaki I, et al:Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 161:1878-1886.e2, 2021.
 
4) Kato K, Ito Y, Daiko H, et al:A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimens as neoadjuvant treatment for locally advanced esophageal cancer, JCOG 1109 NExT study. J Clin Oncol 40(4 Suppl):238, 2022.
 
5) 日本食道学会(編):食道癌取扱い規約(第12版), 金原出版, 2022.
 
6) Takeuchi H, Ito Y, Machida R, et al:A single-arm confirmatory study of definitive chemoradiation therapy including salvage treatment for clinical stage II/III esophageal squamous cell carcinoma (JCOG0909 study). Int J Radiat Biol Phys 114:455-462, 2022.
 
7) Yokota T, Kato K, Hamamoto Y, et al:A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Ann Surg Oncol 27:460-467, 2020.
PubMed
8) Terada M, Hara H, Daiko H, et al:Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510:TRIANgLE). Jpn J Clin Oncol 49:1055-1060, 2019.
PubMed
9) Kelly RJ, Ajani JA, Kuzdzal J, et al:Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med 384:1191-1203, 2021.
PubMed
10) Yamasaki M, Miyata H, Yamashita K, et al:Chemoradiotherapy versus triplet chemotherapy as initial therapy for T4b esophageal cancer:survival results from a multicenter randomized phase 2 trial. Br J Cancer 129:54-60, 2023.
PubMed
11) Kajiwara Y, Takahashi A, Ueno H, et al:Annual report on National Clinical Database 2020 for gastroenterological surgery in Japan. Ann Gastroenterol Surg 7:367-406, 2023.
PubMed
12) Takeuchi H, Ando M, Tsubosa Y, et al:A randomized controlled phase III trial comparing thoracoscopic esophagectomy and open esophagectomy for thoracic esophageal cancer:JCOG1409 (MONET trial). J Clin Oncol 42(3 Suppl):249, 2024.
 
13) Yoshida N, Yamamoto H, Baba H, et al:Can Minimally Invasive Esophagectomy Replace Open Esophagectomy for Esophageal Cancer? Latest Analysis of 24,233 Esophagectomies From the Japanese National Clinical Database. Ann Surg 272:118-124, 2020.
 
14) Okamura A, Endo H, Watanabe M, et al:Influence of patient position in thoracoscopic esophagectomy on postoperative pneumonia:a comparative analysis from the National Clinical Database in Japan. Esophagus 20:48-54, 2023.
PubMed
15) Watanabe M, Kuriyama K, Terayama M, et al:Robotic-Assisted Esophagectomy:Current Situation and Future Perspectives. Ann Thorac Cardiovasc Surg 29:168-176, 2023.
PubMed
P.271 掲載の参考文献
1) Hulscher JB, van Sandick JW, de Boer AG, et al:Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med 347:1662-1669, 2002.
PubMed
2) Omloo JM, Lagarde SM, Hulscher JB, et al:Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus:five-year survival of a randomized clinical trial. Ann Surg 246:992-1001, 2007.
PubMed
3) Sasako M, Sano T, Yamamoto S, et al:Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial. Lancet Oncol 7:644-651, 2006.
PubMed
4) Kurokawa Y, Sasako M, Sano T, et al:Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 102:341-348, 2015.
PubMed
5) Yamashita H, Seto Y, Sano T, et al:Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 20:69-83, 2017.
PubMed
6) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
7) Mine S, Kurokawa Y, Takeuchi H, et al:Distribution of involved abdominal lymph nodes is correlated with the distance from the esophagogastric junction to the distal end of the tumor in Siewert type II tumors. Eur J Surg Oncol 41:1348-1353, 2015.
 
8) Xu Y, Tan Y, Wang Y, et al:Proximal versus total gastrectomy for proximal early gastric cancer:A systematic review and meta-analysis. Medicine (Baltimore) 98:e15663, 2019.
PubMed
9) Cunningham D, Allum WH, Stenning SP, et al:Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006.
PubMed
10) Ychou M, Boige V, Pignon JP, et al:Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715-1721, 2011.
PubMed
11) Petrelli F, Ghidini M, Barni S, et al:Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma:A systematic review and meta-analysis. Gastric Cancer 22:245-254, 2019.
 
12) Kurokawa Y, Kawase T, Takeno A, et al:Phase 2 trial of neoadjuvant docetaxel, oxaliplatin, and S-1 for clinical stage III gastric or esophagogastric junction adenocarcinoma. Ann Gastroenterol Surg 7:247-254, 2023.
PubMed
13) Kita R, Yanagimoto Y, Imazeki H, et al:Stomach Cancer Study Group and Japan Esophageal Oncology Group of the Japan Clinical Oncology Group:Protocol digest of a randomized controlled adaptive Phase II/III trial of neoadjuvant chemotherapy for Japanese patients with oesophagogastric junction adenocarcinoma:Japan Clinical Oncology Group Study JCOG2203 (NEO-JPEG). Jpn J Clin Oncol 54:206-211, 2024.
 
P.277 掲載の参考文献
1) 日本消化器内視鏡学会食道癌に対するESD/EMRガイドライン委員会(編):食道癌に対するESD/EMRガイドライン. Gastroenterol Endosc 62:221-271, 2020.
 
2) 日本食道学会(編):食道癌診療ガイドライン 2022年版 第5版, 金原出版, 2022.
 
3) Brodmerkel GJ:Shiller's test;an aid in esophagoscopic diagnosis. Gastroenterology 60:813-821, 1971.
 
4) Eguchi T, Nakanishi Y, Shimoda T, et al:Histopathological criteria for additional treatment after endoscopic mucosal resection for esophageal cancer:analysis of 464 surgically resected cases. Mod Pathol 19:475-480, 2006.
 
5) Takahashi H, Arimura Y, Masao H, et al:Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 72:255-264.e2642, 2010.
 
6) Yamashina T, Ishihara R, Nagai K, et al:Long-term outcome and metastatic risk after endoscopic resection of superficial esophageal squamous cell carcinoma. Am J Gastroenterol 108:544-551, 2013.
PubMed
7) Thosani N, Singh H, Kapadia A, et al:Diagnostic accuracy of EUS in differentiating mucosal versus submucosal invasion of superficial esophageal cancers:a systematic review and meta-analysis. Gastrointest Endosc 75:242-253, 2012.
PubMed
8) Sato H, Inoue H, Ikeda H, et al:Utility of intrapapillary capillary loops seen on magnifying narrowband imaging in estimating invasive depth of esophageal squamous cell carcinoma. Endoscopy 47:122-128, 2015.
PubMed
9) Ono S, Fujishiro M, Niimi K, et al:Predictors of postoperative stricture after esophageal endoscopic submucosal dissection for superficial squamous cell neoplasms. Endoscopy 41:661-665, 2009.
PubMed
10) Hanaoka N, Ishihara R, Takeuchi Y, et al:Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer:a controlled prospective study. Endoscopy 44:1007-1011, 2012.
PubMed
11) 日本食道学会(編):食道癌診療ガイドライン 2017年版 第4版, 金原出版, 2017.
 
12) Uesato M, Murakami K, Nabeya Y, et al:Preserving the Mucosa to the Maximum Possible Extent for Endoscopic Submucosal Dissection of Subcircumferential Superficial Esophageal Carcinoma. Gastroenterol Res Pract 2018:3540204, 2018
 
13) Minashi K, Nihei K, Mizusawa J, et al:Efficacy of Endoscopic Resection and Selective Chemoradiotherapy for Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 157:382-390.e3, 2019.
 
14) Yamashina T, Ishihara R, Uedo N, et al:Safety and curative ability of endoscopic submucosal dissection for superficial esophageal cancers at least 50 mm in diameter. Dig Endosc 24:220-225, 2012.
PubMed
15) Miwata T, Oka S, Tanaka S, et al:Risk factors for esophageal stenosis after entire circumferential endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Surg Endosc 30:4049-4056, 2016.
PubMed
P.284 掲載の参考文献
1) Ishihara R, Iishi H, Uedo N, et al:Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc 68:1066-1072, 2008.
PubMed
2) Takahashi H, Arimura Y, Masao H, et al:Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 72:255-264.e2642, 2010.
 
3) 門馬久美子, 吉田操, 山田義也, ほか:早期食道癌に対する内視鏡的粘膜切除の実際-2チャンネル法. 胃と腸 28:141-151, 1993.
 
4) Inoue H, Takeshita K, Hori H, et al:Endoscopic mucosal resection with a cap-fitted panendoscope for esophagus, stomach, and colon mucosal lesions. Gastrointest Endosc 39:58-62, 1993.
PubMed
5) Makuuchi H:Endoscopic Mucosal Resection for Early Esophageal Cancer. Dig Endosc 8:175-179, 1996.
 
6) Oyama T, Tomori A, Hotta K, et al:Endoscopic submucosal dissection of early esophageal cancer. Clin Gastroenterol Hepatol 3:S67-S70, 2005.
PubMed
7) Tsujii Y, Nishida T, Nishiyama O, et al:Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms:a multicenter retrospective cohort study. Endoscopy 47:775-783, 2015.
PubMed
8) Koike Y, Hirasawa D, Fujita N, et al:Usefulness of the thread-traction method in esophageal endoscopic submucosal dissection:randomized controlled trial. Dig Endosc 27:303-309, 2015.
PubMed
9) Ishihara R, Arima M, Iizuka T, et al:Endoscopic submucosal dissection/endoscopic mucosal resection guidelines for esophageal cancer. Dig Endosc 32:452-493, 2020.
PubMed
10) 小山恒男:食道ESDのコツと治療成績, 今後の可能性. 消化器内視鏡 17:577-582, 2005.
 
11) Zhai Y, Linghu E, Li H:Double-tunnel endoscopic submucosal tunnel dissection for circumferential superficial esophageal neoplasms. Endoscopy 46(Suppl 1):E204-E205, 2014.
 
12) Zhai YQ, Li HK, Linghu EQ:Endoscopic submucosal tunnel dissection for large superficial esophageal squamous cell neoplasms. World J Gastroenterol 22:435-445, 2016.
PubMed
13) Fan X, Wu Q, Li R, et al:Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer:a multicenter, randomized controlled trial. Gastrointest Endosc 96:436-444, 2022.
 
14) Akasaka T, Takeuchi Y, Uedo N, et al:"Underwater" endoscopic submucosal dissection for superficial esophageal neoplasms. Gastrointest Endosc 85:251-252, 2017.
PubMed
15) Masunaga T, Kato M, Yahagi N:Successful endoscopic submucosal dissection using the water pressure method for cervical esophageal cancer. Dig Endosc 33:e93-e94, 2021.
PubMed
16) Tanaka I, Hirasawa D, Saito H, et al:Stepwise endoscopic submucosal dissection for circumferential Barrett's esophageal dysplasia and carcinoma:a case series. Endosc Int Open 10:E215-E221, 2022.
 
17) Farin G, Grund KE:Technology of argon plasma coagulation with particular regard to endoscopic applications. Endosc Surg Allied Technol 2:71-77, 1994.
PubMed
18) Kawada K, Kawano T, Momma K, et al:New Argon Plasma Coagulation Method for Superficial Esophageal Carcinomas:Argon Plasma Coagulation-Subepithelial Ablation. Dig Endosc 19:147-152, 2007.
 
19) Tahara K, Tanabe S, Ishido K, et al:Argon plasma coagulation for superficial esophageal squamous-cell carcinoma in high-risk patients. World J Gastroenterol 18:5412-5417, 2012.
PubMed
20) Saisho K, Tanaka T, Matono S, et al:Argon plasma coagulation for superficial squamous cell carcinoma in the residual esophagus after esophagectomy. Esophagus 17:448-455, 2020.
PubMed
P.290 掲載の参考文献
1) Ono S, Fujishiro M, Niimi K, et al:Long-term outcomes of endoscopic submucosal dissection for superficial esophageal squamous cell neoplasms. Gastrointest Endosc 70:860-866, 2009.
PubMed
2) Isomoto H, Yamaguchi N, Minami H, et al:Management of complications associated with endoscopic submucosal dissection/ endoscopic mucosal resection for esophageal cancer. Dig Endosc 25(Suppl 1):29-38, 2013.
 
3) Horie Y, Horiuchi Y, Ishiyama A, et al:The effect of antithrombotic drug use on delayed bleeding with esophageal endoscopic resection. J Gastroenterol Hepatol 37:1792-1800, 2022.
PubMed
4) Kawata N, Murai K, Hosotani K, et al:Treating delayed perforation after esophageal endoscopic submucosal dissection using polyglycolic acid sheets and fibrin glue. Endoscopy 55:E446-E447, 2023.
PubMed
5) Iwatsubo T, Takeuchi T, Lee SW, et al:Very Delayed Perforation after Esophageal Endoscopic Submucosal Dissection and Intralesional Triamcinolone Injection. Case Rep Gastroenterol 16:462-468, 2022.
PubMed
6) Omae M, Konradsson M, Baldaque-Silva F:Delayed perforation after endoscopic submucosal dissection treated successfully by temporary stent placement. Clin J Gastroenterol 11:118-122, 2018.
PubMed
7) Matsuda Y, Kataoka N, Yamaguchi T, et al:Delayed esophageal perforation occurring with endoscopic submucosal dissection:A report of two cases. World J Gastrointest Surg 7:123-127, 2015.
PubMed
8) Sato H, Inoue H, Ikeda H, et al:Clinical experience of esophageal perforation occurring with endoscopic submucosal dissection. Dis Esophagus 27:617-622, 2014.
PubMed
9) Tsujii Y, Nishida T, Nishiyama O, et al:Clinical outcomes of endoscopic submucosal dissection for superficial esophageal neoplasms:a multicenter retrospective cohort study. Endoscopy 47:775-783, 2015.
PubMed
10) Hatta W, Koike T, Okata H, et al:Continuous liquid-suction catheter attachment for endoscope reduces volume of liquid reflux to the mouth in esophageal endoscopic submucosal dissection. Dig Endosc 31:527-534, 2019.
 
11) Taniguchi Y, Ono J, Haraguchi M, et al:Impact of low pharyngeal/esophageal pressure associated with sarcopenia on postendoscopic submucosal dissection pneumonia in patients with superficial esophageal cancer. Dig Endosc, 2023. (DOI:10.1111/den.14715).
 
12) 石原立, 有馬美和子, 飯塚敏郎, ほか:食道癌に対するESD/EMRガイドライン. Gastroenterol Endosc 62:221-271, 2020.
 
13) 日本食道学会(編):食道癌診療ガイドライン 2022年版(第5版), 金原出版, 2022.
 
14) 高橋亜紀子, 小山恒男:消化管狭窄に対する内視鏡的バルーン拡張術-食道癌ESD後狭窄のEBD. 臨牀消化器内科 38:529-535, 2023.
 
15) Hikichi T, Nakamura J, Takasumi M, et al:Prevention of Stricture after Endoscopic Submucosal Dissection for Superficial Esophageal Cancer:A Review of the Literature. J Clin Med 10:20, 2020.
PubMed
16) Tanaka M, Ono H, Takizawa K, et al:A randomized controlled phase 3 trial comparing oral prednisolone administration and local triamcinolone injection therapy for the prevention of esophageal stricture after endoscopic submucosal dissection, JCOG1217. United European Gastroenterology Week 2022 Oct 2022, Vienna, Austria.
 
P.296 掲載の参考文献
1) Nakajima Y, Kawada K, Tokairin Y, et al:"Larynx-preserving surgery" for cervical esophageal carcinoma can preserve the vocal function and improve the clinical outcome. Esophagus 14:76-83, 2017.
 
2) Watanabe A, Taniguchi M, Kimura Y, et al:Larynx-preserving hybrid surgery with endoscopic laryngopharyngeal surgery and open surgery for cervical esophageal cancer invading pharynx. Dis Esophagus 33:doaa020, 2020.
PubMed
3) Nakajima Y, Tachimori H, Miyawaki Y, et al:A survey of the clinical outcomes of cervical esophageal carcinoma surgery focusing on the presence or absence of laryngectomy using the National Clinical Database in Japan. Esophagus 19:569-575, 2022.
PubMed
4) Miyawaki Y, Tachimori H, Nakajima Y, et al:Surgical outcomes of reconstruction using the gastric tube and free jejunum for cervical esophageal cancer:analysis using the National Clinical Database of Japan. Esophagus 20:427-434, 2023.
PubMed
5) 中島康晃, 川田研郎, 東海林裕, ほか:頸部食道癌に対する手術治療-喉頭温存を目指した手術戦略. 日本気管食道科学会会報 65:447-456, 2014.
Medical*Online
P.301 掲載の参考文献
1) 国立がん研究センターがん対策情報センター:がん情報サービス. [https://ganjoho.jp/public/index.html]
 
2) Bonavina L, Incarbone R, Saino G, et al:Clinical outcome and survival after esophagectomy for carcinoma in elderly patients. Dis Esophagus 16:90-93, 2003.
PubMed
3) Ruol A, Portale G, Zaninotto G, et al:Results of esophagectomy for esophageal cancer in elderly patients:age has little influence on outcome and survival. J Thorac Cardiovasc Surg 133:1186-1192, 2007.
PubMed
4) Pultrum BB, Bosch DJ, Nijsten MW, et al:Extended esophagectomy in elderly patients with esophageal cancer:minor effect of age alone in determining the postoperative course and survival. Ann Surg Oncol 17:1572-1580, 2010.
PubMed
5) Poon RT, Law SY, Chu KM, et al:Esophagectomy for carcinoma of the esophagus in the elderly:results of current surgical management. Ann Surg 227:357-364, 1998.
PubMed
6) Weimann A, Braga M, Carli F, et al:ESPEN guideline:clinical nutrition in surgery. Clin Nutr 36:623-650, 2017.
 
7) Low DE, Allum W, De Manzoni G, et al:Guidelines for Perioperative Care in Esophagectomy:Enhanced Recovery After Surgery (ERAS) Society Recommendations. World J Surg 43:299-330, 2019.
PubMed
8) 食道癌診療ガイドライン 2022年版(日本食道学会編), 金原出版, 2022.
 
9) Kanda M, Koike M, Tanaka C, et al:Feasibility of subtotal esophagectomy with systematic lymphadenectomy in selected elderly patients with esophageal cancer;a propensity score matching analysis. BMC Surg 19:143, 2019.
 
10) Motoyama S, Maeda E, Iijima K, et al;Does Esophagectomy Provide a Survival Advantage to Patients Aged 80 Years or Older? Analyzing 5066 Patients in the National Database of Hospitalbased Cancer Registries in Japan. Ann Surg 276:e16-e23, 2022.
PubMed
11) Takeuchi H, at al:Thoracoscopic Esophagectomy Is Associated With Favorable Survival in Stage I-III Thoracic Esophageal Cancer. 2024 ASCO GASTROINTESTINAL CANCER SYMPOSIUM.
 
P.309 掲載の参考文献
1) Akiyama H, Tsurumaru M, Udagawa H, et al:Radical lymph node dissection for cancer of the thoracic esophagus. Ann Surg 220:364-373, 1994.
PubMed
2) Cuschieri A:Endoscopic subtotal oesophagectomy for cancer using the right thoracoscopic approach. Surg Oncol 2(Suppl 1):3-11, 1993.
 
3) Akaishi T, Kaneda I, Higuchi N, et al:Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy. J Thorac Cardiovasc Surg 112:1533-1541, 1996.
PubMed
4) Takeuchi H, Miyata H, Gotoh M, et al:A risk model for esophagectomy using data of 5354 patients included in a Japanese nationwide web-based database. Ann Surg 260:259-266, 2014.
 
5) Mamidanna R, Bottle A, Aylin P, et al:Short-term outcomes following open versus minimally invasive esophagectomy for cancer in England:a population-based national study. Ann Surg 255:197-203, 2012.
 
6) Nozaki I, Mizusawa J, Kato K, et al:Impact of laparoscopy on the prevention of pulmonary complications after thoracoscopic esophagectomy using data from JCOG0502:a prospective multicenter study. Surg Endosc 32:651-659, 2018.
PubMed
7) 川久保博文, 竹内裕也, 才川義朗:胸腔鏡補助下胸部食道全摘術. 手術 66:1309-1314, 2012.
 
P.315 掲載の参考文献
1) Cuschieri A, Shimi S, Banting S:Endoscopic oesophagectomy through a right thoracoscopic approach. J R Coll Surg Edinb 37:7-11, 1992.
PubMed
2) Peracchia A, Ancona E, Ruol A, et al:Use of mini-invasive procedures in esophageal surgery. Chirurgie 118:305-308, 1992.
PubMed
3) Akaishi T, Kaneda I, Higuchi N, et al:Thoracoscopic en bloc total esophagectomy with radical mediastinal lymphadenectomy. J Thoracic Cardiovasc Surg 112:1533-1540, 1996.
PubMed
4) Palanivelu C, Prakash A, Senthilkumar R, et al:Minimally invasive esophagectomy:thoracoscopic mobilization of the esophagus and mediastinal lymphadenectomy in prone position-experience of 130 patients. J Am Coll Surg 203:7-16, 2006.
PubMed
5) 宇山一朗, 櫻井洋一, 小森義之, ほか:鏡視下食道癌手術そのノウハウ気胸併用腹臥位(腹這い左半側臥位)による胸腔鏡下食道癌手術. 日臨外会誌 68:344, 2007.
 
6) Kaburagi T, Takeuchi H, Kawakubo H, et al:Clinical utility of a novel hybrid position combining the left lateral decubitus and prone positions during thoracoscopic esophagectomy. World J Surg 38:410-418, 2014.
PubMed
P.322 掲載の参考文献
1) Tangoku A, Yoshino S, Abe T, et al:Mediastinoscope-assisted transhiatal esophagectomy for esophageal cancer. Surg Endosc 18:383-389, 2004.
PubMed
2) Mori K, Yamagata Y, Aikou S, et al:Short-term outcomes of robotic radical esophagectomy for esophageal cancer by a nontransthoracic approach compared with conventional transthoracic surgery. Dis Esophagus 29:429-434, 2016.
PubMed
3) Fujiwara H, Shiozaki A, Konishi H, et al:Perioperative outcomes of single-port mediastinoscope-assisted transhiatal esophagectomy for thoracic esophageal cancer. Dis Esophagus 30:1-8, 2017.
PubMed
4) Shiozaki A, Fujiwara H, Murayama Y, et al:Perioperative outcomes of esophagectomy preceded by the laparoscopic transhiatal approach for esophageal cancer. Dis Esophagus 27:470-478, 2014.
PubMed
5) Fujiwara H, Shiozaki A, Konishi H, et al:Single-Port Mediastinoscopic Lymphadenectomy Along the Left Recurrent Laryngeal Nerve. Ann Thorac Surg 100:1115-1117, 2015.
PubMed
6) Shiozaki A, Fujiwara H, Konishi H, et al:Hand-assisted technique beneficial for laparoscopic transhiatal esophagectomy with en-bloc dissection of middle and lower mediastinal lymph nodes:roles of the operator's left hand. Esophagus 14:138-145, 2017.
 
7) 塩崎敦, 藤原斉, 小西博貴, ほか:胸部食道癌に対する手術 非開胸食道切除術. 日本臨牀 76(増刊:食道癌):283-289, 2018.
 
8) 塩崎敦, 藤原斉, 小西博貴, ほか:最新医療機器・材料を使いこなす縦隔鏡下食道切除術における術中神経モニタリングによる反回神経麻痺予防. 臨床外科 78:134-138, 2023.
 
9) 藤原斉, 塩崎敦, 小西博貴, ほか:特集徹底解説術後後遺症をいかに防ぐか-コツとポイント 食道癌縦隔アプローチでの反回神経麻痺-その特徴と術中持続神経モニタリングの有用性. 臨床外科 76:11-18, 2021.
 
10) 藤原斉, 塩崎敦, 小西博貴, ほか:縦隔鏡下食道亜全摘術. 消化器外科 41(増刊):546-555, 2018.
 
11) Maeda T, Fujiwara H, Konishi H, et al:Preoperative 3D-CT evaluation of the bronchial arteries in transmediastinal radical esophagectomy for esophageal cancer. Esophagus 19:77-84, 2022.
 
12) 塩崎敦, 藤原斉, 小西博貴, ほか:経裂孔的縦隔郭清手技における中下縦隔・食道胃接合部の解剖. 手術 71:399-404, 2017.
 
13) 塩崎敦, 藤原斉, 大辻英吾:術野の展開法上部消化管(2)(食道) 食道癌に対する非開胸食道切除術における術野展開. 内視鏡外科手術・役立つテクニック100[Web動画付]宮澤光男(編), p59-61, 医学書院, 2020.
 
14) Schneider R, Randolph GW, Barczynski M, et al:Continuous intraoperative neural monitoring of the recurrent nerves in thyroid surgery:a quantum leap in technology. Gland Surg 5:607-616, 2016.
PubMed
15) Furuke H, Konishi H, Fujiwara H, et al:Predictors of the difficulty of transcervical subcarinal lymph node dissection for esophageal cancer. Esophagus 20:420-426, 2023.
PubMed
P.328 掲載の参考文献
1) 能城浩和, 池田貯, 河野博:胸部食道癌に対する腹臥位ロボット支援手術. 消化器外科 37:23-30, 2014.
 
2) Kernstine KH, DeArmond DT, Karimi M, et al:The robotic, 2-stage, 3-field esophagolymphadenectomy. J Thorac Cardiovasc Surg 127:1847-1849, 2004.
PubMed
3) Suda K, Ishida Y, Kawamura Y, et al:Robot-assisted thoracoscopic lymphadenectomy along the left recurrent laryngeal nerve for esophageal squamous cell carcinoma in the prone position:technical report and short-term outcomes. World J Surg 36:1608-1616, 2012.
PubMed
4) Noshiro H, Miyake S:Thoracoscopic esophagectomy using prone positioning. Ann Thorac Cardiovasc Surg 19:399-408, 2013.
 
5) Tsunoda S, Obama K, Hisamori S, et al:Lower Incidence of Postoperative Pulmonary Complications Following Robot-Assisted Minimally Invasive Esophagectomy for Esophageal Cancer:Propensity Score-Matched Comparison to Conventional Minimally Invasive Esophagectomy. Ann Surg Oncol 28:639-647, 2021.
PubMed
6) Fujita T, Sato K, Ozaki A, et al:Propensity-Matched Analysis of the Short-Term Outcome of Robot-Assisted Minimally Invasive Esophagectomy Versus Conventional Thoracoscopic Esophagectomy in Thoracic Esophageal Cancer. World J Surg 46:1926-1933, 2022.
PubMed
7) 日本内視鏡外科学会:内視鏡外科手術に関するアンケート調査-第16回集計結果報告, 腹部外科領域, 2022.
 
8) Ide T, Ito K, Tanaka T, et al:Robotic distal pancreatectomy using a docking-free system (the hinotori(TM) Surgical Robot System). Surg Oncol 50:101974, 2023.
 
9) Tomihara K, Ide T, Ito K, et al:Robotic spleen-preserving distal pancreatectomy using the first domestic surgical robot platform (the hinotori(TM) Surgical Robot System):a case report. Surg Case Rep 10:22, 2024.
 
10) Tanigawa Y, Nakamura K, Yamashita T, et al:Changes in respiratory mechanics of artificial pneumothorax two-lung ventilation in video-assisted thoracoscopic esophagectomy in prone position. Sci Rep 11:6978, 2021.
PubMed
11) Noshiro H, Okuyama K, Kajiwara S, et al:Initial Learning Curve and Stereotypical Use of Extra Arm During da Vinci Chest Procedures of McKeown Esophagectomy. Innovations (Phila) 17:324-332, 2022.
 
12) 能城浩和, 與田幸恵, 鶴安浩:食道手術-右胸腔アプローチによるロボット支援下食道切除術における縦隔郭清の手術技術-. 消化器外科 46:341-350, 2023.
 
13) Kataoka K, Takeuchi H, Mizusawa J, et al:Prognostic Impact of Postoperative Morbidity After Esophagectomy for Esophageal Cancer:Exploratory Analysis of JCOG9907. Ann Surg 265:1152-1157, 2017.
PubMed
P.334 掲載の参考文献
1) 遠藤光夫, 鈴木博孝, 井出博子, ほか:左開胸開腹横隔膜切開による食道浸潤胃癌の手術術式. 手術 36:313-318, 1982.
 
2) 土江健嗣, 高木国夫, 大橋一郎, ほか:胃癌食道浸潤例に対する左胸腹連続切開法(胴切り法)の検討. 日消外会誌 17:2123-2129, 1984.
 
3) 田村孝史, 三浦昭順, 了徳寺大郎, ほか:食道胃接合部癌に対する非開胸・縦隔鏡補助下経裂孔的下部食道切除の有効性についての検討. 日消外会誌 44:1079-1088, 2011.
 
4) 明石義正, 出江洋介, 加藤剛, ほか:根治切除により長期生存を得たα-fetoprotein産生Barrett腺癌の1例. 日消外会誌 42:355-361, 2009.
 
5) Sobin LH, Gospodarowicz MK, Wittekind C (ed):TNM Classification of Malignant Tumours, 7th ed, Wiley-Blackwell;2009.
 
6) Brierley JD, Gospodarowicz MK, Wittekind C (ed):TNM Classification of Malignant Tumours, 8th ed, Wiley-Blackwell;2016.
 
7) 日本食道学会(編):食道癌診療ガイドライン 第5版, 金原出版, 2022.
 
8) 日本胃癌学会(編):胃癌治療ガイドライン 第6版, 金原出版, 2021.
 
9) Izumi Y:Hybrid laparo-thoracoscopic esophagectomy for esophageal cancer:combined endoscopy-assisted laparoscopic transhiatal and thoracoscopic esophagectomy with artificial pneumothorax. In:Comprehensive Guide to Esophagectomy (ed by Nolan W), p69-101, Nova Science Publishers, New York, 2021.
 
10) 太田俊介, 河野辰幸:左開胸開腹食道切除・リンパ節郭清術. 食道癌診療マニュアル-消化器外科・内科医のための(河野辰幸, 三宅智編), p89-91, 診断と治療社, 2012.
 
11) 吉田操, 門馬久美子, 出江洋介:食道癌診療の歴史と展望. 日本臨牀 69(増刊号6:食道癌):9-16, 2011.
Medical*Online
P.339 掲載の参考文献
1) 日本食道学会(編):食道癌取扱い規約(第12版), 金原出版, 2022.
 
2) 日本胃癌学会(編):胃癌治療ガイドライン 2021年7月改訂(第6版), 金原出版, 2021.
 
3) Yamashita H, Seto Y, Sano T, et al:Results of a nation-wide retrospective study of lymphadenectomy for esophagogastric junction carcinoma. Gastric Cancer 20(Suppl 1):69-83, 2017.
 
4) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
5) Etoh T, Ohyama T, Sakuramoto S, et al:Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer:The JLSSG0901 Randomized Clinical Trial. JAMA Surg 158:445-454, 2023.
PubMed
6) Huang CM, Lv CB, Lin JX, et al:Laparoscopic-assisted versus open total gastrectomy for Siewert type II and III esophagogastric junction carcinoma:a propensity score-matched case-control study. Surg Endosc 31:3495-3503, 2017.
PubMed
7) Mine S, Kurokawa Y, Takeuchi H, et al:Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers:a prospective nationwide multicenter study. Gastric Cancer 25:430-437, 2022.
PubMed
8) 上川康明, 小林達則, 上山聡, ほか:噴門側胃切除後の食道胃吻合法における工夫 徹底した逆流防止と安全性を目指して. 手術 52:1477-1483, 1998.
 
9) Yamashita Y, Yamamoto A, Tamamori Y, et al:Side overlap esophagogastrostomy to prevent reflux after proximal gastrectomy. Gastric Cancer 20:728-735, 2017.
PubMed
10) Xiao JW, Liu ZL, Ye PC, et al:Clinical comparison of antrum-preserving double tract reconstruction vs roux-en-Y reconstruction after gastrectomy for Siewert types II and III adenocarcinoma of the esophagogastric junction. World J Gastroenterol 21:9999-10007, 2015.
PubMed
11) Katai H, Mizusawa J, Katayama H, et al:Survival outcomes after laparoscopy-assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912):a multicentre, non-inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 5:142-151, 2020.
PubMed
12) Omori T, Yamamoto K, Yanagimoto Y, et al:A Novel Valvuloplastic Esophagogastrostomy Technique for Laparoscopic Transhiatal Lower Esophagectomy and Proximal Gastrectomy for Siewert Type II Esophagogastric Junction Carcinoma-the Tri Double-Flap Hybrid Method. J Gastrointest Surg 25:16-27, 2021.
 
13) Wang L, Ma H, Ren P, et al:A Novel Esophagogastrostomy Technique for Laparoscopic Proximal Gastrectomy:Conical Remnant Gastroesophageal Side-overlap Fundoplication. Cancer Diagn Progn 3:609-615, 2023.
PubMed
P.344 掲載の参考文献
1) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
2) Kuroda S, Nishizaki M, Kikuchi S, et al:Double-Flap Technique as an Antireflux Procedure in Esophagogastrostomy after Proximal Gastrectomy. J Am Coll Surg 223:e7-e13, 2016.
PubMed
3) Fujiwara H, Shiozaki H, Konishi H, et al:Perioperative outcomes of single-port mediastinoscope-assisted transhiatal esophagectomy for thoracic esophageal cancer. Dis Esophagus 30:1-8, 2017.
 
4) Fujita T, Sato K, Fujiwara N, et al:Robot-assisted transcervical esophagectomy with a bilateral cervical approach for thoracic esophagectomy. Surg Endosc 38:1-9, 2024
 
5) Daiko H, Oguma J, Fujiwara H, et al:Novel universally applicable technique for performing bilateral transcervical mediastinoscopic-assisted transhiatal laparoscopic esophagectomy:a truly minimally invasive procedure. Surg Endosc 35:5186-5192, 2021.
PubMed
6) Shitara K, Rha SY, Wyrwicz LS, et al:Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585):an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 25:212-224, 2024.
PubMed
7) Janjigian YY, Cutsem EV, Muro K, et al:MATTERHORN:Phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. Future Oncol 18:2465-2473, 2022.
 
P.349 掲載の参考文献
1) Tachimori Y, Ozawa S, Numasaki H, et al:Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 13:110-137, 2016.
PubMed
2) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
3) Sun S, Wang Z, Huang C, et al:Different gastric tubes in esophageal reconstruction during esophagectomy. Esophagus 20:595-604, 2023.
PubMed
4) Yoshida K, Tanaka Y, Imai T, et al:Subtotal stomach in esophageal reconstruction surgery achieves an anastomotic leakage rate of less than 1%. Ann Gastroenterol Surg 4:422-432, 2020.
PubMed
5) 菊池寛利, ほか:食道外科 縫合不全を最小とする胃管再建法 細径胃管の立場から. 手術 74:412-421, 2020.
 
6) Zhang M, Zhang C, Wu QC:Health-related quality of life and survival among 10-year survivors of esophageal cancer surgery:gastric tube reconstruction versus whole stomach reconstruction. J Thorac Dis 11:3284-3291, 2019.
 
7) Booka E, Takeuchi H, Morita Y, et al:What is the best reconstruction procedure after esophagectomy? A meta-analysis comparing posterior mediastinal and retrosternal approaches. Ann Gastroenterol Surg 7:553-564, 2023.
PubMed
8) Koyanagi K, Ozawa S, Ninomiya Y, et al:Indocyanine green fluorescence imaging for evaluating blood flow in the reconstructed conduit after esophageal cancer surgery. Surg Today 52:369-376, 2022.
PubMed
9) 松尾謙太郎, ほか:食道再建のすべて 再建経路. 消化器外科 46:119-128, 2023.
 
10) Yasuda T, Shiraishi O, Kato H, et al:A comparative study of the lengths of different reconstruction routes used after thoracic esophagectomy. Esophagus 18:468-474, 2021.
PubMed
11) Kikuchi H, Endo H, Yamamoto H, et al:Impact of Reconstruction Route on Postoperative Morbidity After Esophagectomy:Analysis of Esophagectomies in the Japanese National Clinical Database. Ann Gastroenterol Surg 6:46-53, 2022.
PubMed
12) 渡邊雅之, ほか:食道再建のすべて 食道再建における吻合方法. 消化器外科 46:157-165, 2023.
 
13) Honda M, Kuriyama A, Noma H, et al:Hand-Sewn Versus Mechanical Esophagogastric anastomosis After Esophagectomy A Systematic Revie and Meta-Analysis. Ann Surg 257:238-248, 2013.
 
14) Deng XF, Liu QX, Zhou D, et al:Hand-sewn vs linearly stapled esophagogastric anastomosis for esophageal cancer:a meta-analysis. World J Gastroenterol 21:4757-4764, 2015.
PubMed
15) Chen B, Xia P, Tang W, et al:Which Anastomotic Techniques Is the Best Choice for Cervical Esophagogastric Anastomosis in Esophagectomy? A Bayesian Network Meta-Analysis. J Gastrointest Surg 27:422-432, 2023.
PubMed
P.357 掲載の参考文献
1) Roux C:A new operation for intractable obstruction of the esophagus (L'oesophago-jejuno-gastrosiose, nouvelle operation pour retrecissement infrachissable del'oesophagus). Semin Med 27:34-40, 1907.
 
2) Yudin SS:The surgical construction of 80 cases of artificial esophagus. Surg Gynecol Obstet 78:561-583, 1944.
 
3) Ochsner A, Owens N:Anterothoracic Oesophagoplasty for Impermeable Stricture of the Oesophagus. Ann Surg 100:1055-1091, 1934.
PubMed
4) Longmire WP Jr:A modification of the Roux technique for antethoracic esophageal reconstruction. Surgery 22:94-100, 1947.
PubMed
5) Androsov PI:Blood supply of mobilized intestine used for an artificial esophagus. AMA Arch Surg 73:917-926, 1956.
PubMed
6) Hirabayashi S, Miyata M, Shoji M, et al:Reconstruction of the thoracic esophagus, with extended jejunum used as a substitute, with the aid of microvascular anastomosis. Surgery 113:515-519, 1993.
PubMed
7) Chana JS, Chen HC, Sharma R, et al:Microsurgical reconstruction of the esophagus using supercharged pedicled jejunum flaps:special indications and pitfalls. Plast Reconstr Surg 110:742-750, 2002.
PubMed
8) Ascioti AJ, Hofstetter WL, Miller MJ, et al:Long-segment, supercharged, pedicled jejunal flap for total esophageal reconstruction. J Thorac Cardiovasc Surg 130:1391-1398, 2005.
PubMed
9) Ueda K, Kajikawa A, Suzuki Y, et al:Blood gas analysis of the jejunum in the supercharge technique:to what degree does circulation improve? Plast Reconstr Surg 119:1745-1750, 2007.
PubMed
10) Doki Y, Okada K, Miyata H, et al:Long-term and short-term evaluation of esophageal reconstruction using the colon or the jejunum in esophageal cancer patients after gastrectomy. Dis Esophagus 21:132-138, 2008.
PubMed
11) Yasuda T, Shiozaki H:Esophageal reconstruction using a pedicled jejunum with microvascular augmentation. Ann Thorac Cardiovasc Surg 17:103-109, 2011.
PubMed
12) Watanabe M, Mine S, Nishida K, et al:Reconstruction after esophagectomy for esophageal cancer patients with a history of gastrectomy. Gen Thorac Cardiovasc Surg 64:457-463, 2016.
PubMed
13) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2014. Esophagus 19:1-26, 2022.
 
P.361 掲載の参考文献
1) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
2) Watanabe M, Mine S, Nishida K, et al:Reconstruction after esophagectomy for esophageal cancer patients with a history of gastrectomy. Gen Thorac Cardiovasc Surg 64:457-463, 2016.
PubMed
3) Popovici Z:A new philosophy in esophageal reconstruction with colon. Thirty-years experience. Dis Esophagus 16:323-327, 2003.
PubMed
P.366 掲載の参考文献
1) Watanabe M, Tachimori Y, Oyama T, et al:Comprehensive registry of esophageal cancer in Japan, 2013. Esophagus 18:1-24, 2021.
PubMed
2) Tachimori Y, Ozawa S, Numasaki H, et al:Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 13:110-137, 2016.
PubMed
3) Kurokawa Y, Sasako M, Sano T, et al:Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 102:341-348, 2015.
PubMed
4) Sasako M, Sano T, Yamamoto S, et al:Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia:a randomised controlled trial. Lancet Oncol 7:644-651, 2006.
PubMed
5) Kurokawa Y, Takeuchi H, Doki Y, et al:Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors:A Prospective Nationwide Multicenter Study. Ann Surg 274:120-127, 2021.
PubMed
6) Japanese Gastric Cancer Association:Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 26:1-25, 2023.
 
7) Mine S, Kurokawa Y, Takeuchi H, et al:Postoperative complications after a transthoracic esophagectomy or a transhiatal gastrectomy in patients with esophagogastric junctional cancers:a prospective nationwide multicenter study. Gastric Cancer 25:430-437, 2022.
PubMed
8) 上川康明, 小林達則, 上山聡:噴門側胃切除後の逆流防止を目指した新しい食道胃吻合法. 消化器外科 24:1053-1060, 2001.
 
9) Hosoda K, Yamashita K, Moriya H, et al:Laparoscopically Assisted Proximal Gastrectomy with Esophagogastrostomy Using a Novel "Open-Door" Technique:LAPG with Novel Reconstruction. J Gastrointest Surg 21:1174-1180, 2017.
PubMed
10) Hosoda K, Washio M, Mieno H, et al:Comparison of double-flap and OrVil techniques of laparoscopy-assisted proximal gastrectomy in preventing gastroesophageal reflux:a retrospective cohort study. Langenbecks Arch Surg 404:81-91, 2019.
PubMed
11) Hayami M, Hiki N, Nunobe S, et al:Clinical Outcomes and Evaluation of Laparoscopic Proximal Gastrectomy with Double-Flap Technique for Early Gastric Cancer in the Upper Third of the Stomach. Ann Surg Oncol 24:1635-1642, 2017.
PubMed
12) Shoji Y, Nunobe S, Ida S, et al:Surgical outcomes and risk assessment for anastomotic complications after laparoscopic proximal gastrectomy with double-flap technique for upper-third gastric cancer. Gastric Cancer 22:1036-1043, 2019.
PubMed
P.373 掲載の参考文献
1) Hironaka S, Ohtsu A, Boku N, et al:Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3) N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 57:425-433, 2003.
 
2) 日本食道学会編:食道癌取扱い規約 第12版, 金原出版, 2022.
 
3) 日本食道学会編:食道癌診療ガイドライン 2022年版, 金原出版, 2022.
 
4) Kato K, Muro K, Minashi K, et al:Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma:JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684-690, 2011.
PubMed
5) Nomura M, Kato K, Ando N, et al:Comparison between neoadjuvant chemotherapy followed by surgery and definitive chemoradiotherapy for overall survival in patients with clinical Stage II/III esophageal squamous cell carcinoma (JCOG1406-A). Jpn J Clin Oncol 47:480-486, 2017.
PubMed
6) 亀井尚, 宮田剛, 小野寺浩, ほか:切除可能食道癌に対する治療戦略-salvage治療を付加した化学放射線療法と根治手術の成績. 臨牀消化器内科 26:1381-1387, 2011.
 
7) Takeuchi H, Ito Y, Machida R, et al:A Single-Arm Confirmatory Study of Definitive Chemoradiation Therapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study). Int J Radiat Oncol Biol Phys 114:455-462, 2022.
 
8) Okamura A, Hayami M, Kozuki R, et al:Salvage esophagectomy for initially unresectable locally advanced T4 esophageal squamous cell carcinoma. Esophagus 17:59-66, 2020.
PubMed
9) Defize IL, van der Horst S, Bulbul M, et al:Salvage Robot-Assisted Minimally Invasive Esophagectomy (RAMIE) for T4b Esophageal Cancer After Definitive Chemoradiotherapy. Ann Surg Oncol 28:2730-2738, 2021.
PubMed
10) Taniyama Y, Sakurai T, Heishi T, et al:Different strategy of salvage esophagectomy between residual and recurrent esophageal cancer after definitive chemoradiotherapy. J Thorac Dis 10:1554-1562, 2018.
PubMed
11) Yokota T, Kato K, Hamamoto Y, et al:A 3-Year Overall Survival Update From a Phase 2 Study of Chemoselection With DCF and Subsequent Conversion Surgery for Locally Advanced Unresectable Esophageal Cancer. Ann Surg Oncol 27:460-467, 2020.
PubMed
12) Abe T, Higaki E, Hosoi T, et al:Long-Term Outcome of Patients with Locally Advanced Clinically Unresectable Esophageal Cancer Undergoing Conversion Surgery after Induction Chemotherapy with Docetaxel Plus Cisplatin and 5-Fluorouracil. Ann Surg Oncol 28:712-721, 2021.
PubMed
13) Sugimura K, Miyata H, Tanaka K, et al:Multicenter Randomized Phase 2 Trial Comparing Chemoradiotherapy and Docetaxel Plus 5-Fluorouracil and Cisplatin Chemotherapy as Initial Induction Therapy for Subsequent Conversion Surgery in Patients with Clinical T4b Esophageal Cancer:Short-term Results. Ann Surg 274:e465-e472, 2021.
PubMed
14) Terada M, Hara H, Daiko H, et al:Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510:TRIANgLE). Jpn J Clin Oncol 49:1055-1060, 2019.
PubMed
15) Huang S, Wu H, Cheng C, et al:Conversion Surgery Following Immunochemotherapy in Initially Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma-A Real-World Multicenter Study (RICE-Retro). Front Immunol 13:935374, 2022.
 
P.379 掲載の参考文献
1) Oken MM, Creech RH, Tormey DC, et al:Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982.
 
2) Fekete F, Belghiti J, Cherqui D, et al:Results of esophagogastrectomy for carcinoma in cirrhotic patients. A series of 23 consecutive patients. Ann Surg 206:74-78, 1987.
PubMed
3) Imamura M, Shimada Y, Kanda T, et al:Hemodynamic changes after resection of thoracic duct for en bloc resection of esophageal cancer. Surg Today 22:226-232, 1992.
PubMed
4) Preiser JC, Devos P, Ruiz-Santana S, et al:A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units:the Glucontrol study. Intensive Care Med 35:1738-1748, 2009.
PubMed
5) 食道癌診療ガイドライン 2022年版(日本食道学会編), 金原出版, 2022.
 
6) Gronkjaer M, Eliasen M, Skov-Ettrup LS, et al:Preoperative smoking status and postoperative complications:a systematic review and meta-analysis. Ann Surg 259:52-71, 2014.
PubMed
7) Theadom A, Cropley M:Effects of preoperative smoking cessation on the incidence and risk of intraoperative and postoperative complications in adult smokers:a systematic review. Tob Control 15:352-358, 2006.
PubMed
8) Hulzebos EH, Helders PJ, Favie NJ, et al:Preoperative intensive inspiratory muscle training to prevent postoperative pulmonary complications in high-risk patients undergoing CABG surgery:a randomized clinical trial. JAMA 296:1851-1857, 2006.
PubMed
9) Akutsu Y, Matsubara H, Shuto K, et al:Pre-operative dental brushing can reduce the risk of postoperative pneumonia in esophageal cancer patients. Surgery 147:497-502, 2010.
PubMed
10) Fukuda T, Seto Y, Yamada K, et al:Can immune-enhancing nutrients reduce postoperative complications in patients undergoing esophageal surgery? Dis Esophagus 21:708-711, 2008.
PubMed
11) Low DE, Kunz S, Schembre D, et al:Esophagectomy-it's not just about mortality anymore:standardized perioperative clinical pathways improve outcomes in patients with esophageal cancer. J Gastrointest Surg 11:1395-1402, 2007.
 
12) Munitiz V, Martinez-de-Haro LF, Ortiz A, et al:Effectiveness of a written clinical pathway for enhanced recovery after transthoracic (Ivor Lewis) oesophagectomy. Br J Surg 97:714-718, 2010.
 
13) Shimada H, Ochiai T, Okazumi S, et al:Clinical benefits of steroid therapy on surgical stress in patients with esophageal cancer. Surgery 128:791-798, 2000.
 
14) Okazumi S, Ochiai T, Shimada H, et al:Development of less invasive surgical procedures for thoracic esophageal cancer. Dis Esophagus 17:159-163, 2004.
PubMed
15) Shuto K, Kano T, Akutsu Y, et al:Naso-esophageal extraluminal drainage for postoperative anastomotic leak after thoracic esophagectomy for patients with esophageal cancer. Dis Esophagus 30:1-9, 2017.
 
P.385 掲載の参考文献
1) 鍋谷圭宏, 加野将之, 水藤広, ほか:食道癌手術における周術期感染管理. 日外感染会誌 20:92-100, 2023.
 
2) 鍋谷圭宏:高齢者食道癌治療における栄養管理. 日本気管食道科学会「専門医通信」62:26-32, 2021.
 
3) 亀井尚, 小澤洋平, 谷山裕亮, ほか:サルコペニア併存食道癌患者に対する術前・術後栄養管理とリハビリテーション. 外科と代謝・栄養 56:209-213, 2022.
Medical*Online
4) Chen LK, Woo J, Assantachai P, et al:Asian Working Group for Sarcopenia:2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc 21:300-307.e2, 2020.
 
5) 豊島堅志:フレイルのUPDATE-診断・評価を中心に. 臨床栄養 144:314-321, 2024.
Medical*Online
6) 安枝明日香, 西村潤一, 池田聖児, ほか:消化器癌切除術施行症例におけるフレイルの現状と短期成績. 外科と代謝・栄養 57:127-134, 2023.
Medical*Online
7) Nabeya Y, Hoshino I, Nagata M, et al:Perioperative management for early recovery after esophageal cancer surgery. In:Enhanced Recovery after Surgery (ed by Fukushima R, Kaibori M), p73-79, Springer, Singapore, 2018.
 
8) Cederholm T, Jensen GL, Correia MITD, et al:GLIM criteria for the diagnosis of malnutrition - A consensus report from the global clinical nutrition community. Clin Nutr 38:1-9, 2019.
PubMed
9) Onishi S, Tajika M, Tanaka T, et al:Prognostic Impact of Sarcopenic Obesity after Neoadjuvant Chemotherapy Followed by Surgery in Elderly Patients with Esophageal Squamous Cell Carcinoma. J Clin Med 9:2974, 2020.
PubMed
10) Morito A, Harada K, Iwatsuki M, et al:Frailty Assessed by the Clinical Frailty Scale is Associated with Prognosis After Esophagectomy. Ann Surg Oncol 30:3725-3732, 2023.
PubMed
11) Motoori M, Fujitani K, Sugimura K, et al:Skeletal Muscle Loss during Neoadjuvant Chemotherapy Is an Independent Risk Factor for Postoperative Infectious Complications in Patients with Advanced Esophageal Cancer. Oncology 95:281-287, 2018.
PubMed
12) Harada T, Tatematsu N, Ueno J, et al:Prognostic Impact of Postoperative Loss of Skeletal Muscle Mass in Patients Aged 70 Years or Older with Esophageal Cancer. Ann Surg Oncol 29:5638-5645, 2022.
PubMed
13) Kudou K, Saeki H, Nakashima Y, et al:Postoperative development of sarcopenia is a strong predictor of a poor prognosis in patients with adenocarcinoma of the esophagogastric junction and upper gastric cancer. Am J Surg 217:757-763, 2019.
 
14) An KR, Seijas V, Xu MS, et al:Does prehabilitation before esophagectomy improve postoperative outcomes? A systematic review and meta-analysis. Dis Esophagus 37:doad066, 2024.
PubMed
15) Hijikata N, Ishikawa A, Matsuda S, et al:Effect of Postoperative Oral Intake Status on Sarcopenia Six Months After Esophageal Cancer Surgery. Dysphagia 38:340-350, 2023. (Correction:Dysphagia 38:351-352, 2023.)
 
P.392 掲載の参考文献
1) Takeuchi H, Miyata H, Ozawa S, et al:Comparison of Short-Term Outcomes Between Open and Minimally Invasive Esophagectomy for Esophageal Cancer Using a Nationwide Database in Japan. Ann Surg Oncol 24:1821-1827, 2017.
PubMed
2) 坊岡英祐, 江川智久, 川久保博文, ほか:食道癌手術における術前治療と術後感染性合併症との関連. 日本外科感染症学会雑誌 16:133-135, 2019.
Medical*Online
3) 坊岡英祐, 菊池寛利, 羽田綾馬, ほか:ロボット支援下胸部食道切除術の術後短期成績の検討. 外科と代謝・栄養 56:196-201, 2022.
Medical*Online
4) 青山純也, 川久保博文, 安藤牧子, ほか:食道癌手術. 消化器外科 44:495-503, 2021.
 
5) 丸山弘, 牧野浩司:術後肺炎. 日本外科感染症学会雑誌 19:416-424, 2022.
Medical*Online
6) Matsunaga T, Miyata H, Sugimura K, et al:Clinical usefulness of a perioperative bacteriological culture to treat patients with postoperative pneumonia after esophagectomy. Ann Gastroenterol Surg 3:57-64, 2018.
PubMed
7) 上野正紀, ほか:術後合併症とその管理(4)肺炎. 消化器外科 35(増刊:術前・術後管理必携):859-861, 2012.
 
8) 鍋谷圭宏, 星野敢:食道手術におけるドレーンの適正使用. 日本外科感染症学会雑誌 15:167-173, 2018.
Medical*Online
9) Takeoka T, Miyata H, Sugimura K, et al:Modified Collard technique is more effective than circular stapled for cervical esophagogastric anastomosis in prevention of anastomotic stricture:a propensity score-matched study. Dis Esophagus 36:doac077, 2023.
PubMed
10) Shuto K, Kono T, Akutsu Y, et al:Naso-esophageal extraluminal drainage for postoperative anastomotic leak after thoracic esophagectomy for patients with esophageal cancer. Dis Esophagus 30:1-9, 2017.
PubMed
11) Kosumi K, Baba Y, Ozaki N, et al:Transnasal inner drainage:an option for managing anastomotic leakage after esophagectomy. Langenbecks Arch Surg 401:903-908, 2016.
PubMed
12) 北野正剛:食道の手術後の合併症食道切除術後の嗄声と術後7日目の発熱. 消化器外科 周術期合併症のminimal requirements(白石憲男, 上田貴威編), p310-317, メジカルビュー社, 2015.
 
13) 小柳和夫, 小澤壯治, 二宮大和, ほか:食道切除後の早期広範囲胃管壊死に対する対処. 手術 75:1119-1124, 2021.
 
14) 本山悟, 佐藤雄亮:食道癌術後胸腔内合併症に対する再手術(乳び胸, 気管・気管支瘻, 後出血). 胸部外科 74:883-889, 2021.
 
15) 安田卓司, 白石治, 加藤寛章, ほか:食道切除後(術後)気管・気管支壊死または瘻孔形成に対する対処. 手術 75:1125-1133, 2021.
 
16) 花田圭太, 畑啓昭, 大谷哲之, ほか:鼠径リンパ節穿刺によるリンパ管造影が有用であった食道癌術後乳糜胸の1例. 日本臨床外科学会雑誌 77:322-327, 2016.
 
17) 大倉遊, 上野正紀, 宇多川晴司:食道切除後難治性リンパ瘻・乳び胸に対する対処. 手術 75:1143-1146, 2021.
 
P.398 掲載の参考文献
1) Watanabe M, Toh Y, Ishihara R, et al:Comprehensive registry of esophageal cancer in Japan, 2015. Esophagus 20:1-28, 2023.
PubMed
2) 一般社団法人日本医療安全調査機構:医療事故調査・支援センター2022年報, p15, 一般社団法人日本医療安全機構, 2023.
 
3) 中島和江:レジリエンス・エンジニアリングの医療安全への応用. 日本手術医学会誌 36:239-241, 2015.
Medical*Online
4) WHO患者安全カリキュラムガイド:多職種版2011, トピック4:有能なチームの一員であること. p131-148. 東京医科大学医学教育学・医療安全管理学, 2012.
 
5) WHO患者安全カリキュラムガイド:多職種版2011, トピック5:エラーに学び, 害を防止する. p149-159. 東京医科大学医学教育学・医療安全管理学, 2012.
 
6) 小松康宏, 門田美和子, 福井次矢:医療の質改善の概念と手法-PDCA. six sigmaなど. 日本内科学会雑誌 105:2353-2357, 2016.
 
7) 古谷健夫:PDCAとSDCAの融合. お客様の満足を高めるSDCA, p30-34, 日科技連, 2022.
 
8) 一般社団法人National Clinical Database HP, NCD Feedback. [https://registry3.ncd.or.jp](2024年2月閲覧)
 
P.405 掲載の参考文献
1) 国立がん研究センター:がん情報サービス, がん種別統計情報, 食道. [https://ganjoho.jp/reg_stat/statistics/stat/cancer/4_esophagus.html#anchor1]
 
2) Hamamoto Y, Akutsu Y, Nagashima F, et al:Multicenter questionnaire survey on patterns of care for elderly patients with esophageal squamous cell carcinoma by the Japan Esophageal Oncology Group. Jpn J Clin Oncol 46:111-115, 2016.
PubMed
3) Wildiers H, Heeren P, Puts M, et al:International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32:2595-2603, 2014.
 
4) Decoster L, Van Puyvelde K, Mohile S, et al:Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients:an update on SIOG recommendations. Ann Oncol 26:288-300, 2015.
PubMed
5) 日本臨床腫瘍研究グループ:JCOG 高齢者研究ポリシー2016. [https://jcog.jp/A_020_0010_39.pdf]
 
6) Kato K, Ito Y, Daiko H, et al:A randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer, JCOG1109 NExT study. J Clin Oncol 40(Suppl):238, 2022.
 
7) Kelly RJ, Ajani JA, Kuzdzal J, et al:Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N Engl J Med 384:1191-1203, 2021.
PubMed
8) Matsuda S, Kitagawa Y, Takemura R, et al:Real-world Evaluation of the Efficacy of Neoadjuvant DCF Over CF in Esophageal Squamous Cell Carcinoma:Propensity Score-matched Analysis From 85 Authorized Institutes for Esophageal Cancer in Japan. Ann Surg 278:e35-e42, 2023.
PubMed
9) Booka E, Haneda R, Ishii K, et al:The Negative Impact of Preoperative Chemotherapy on Survival After Esophagectomy for Vulnerable Elderly Patients with Esophageal Cancer. Ann Surg Oncol 28:1786-1795, 2021.
PubMed
10) Saito Y, Hamamoto Y, Hirata K, et al:Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma:a multicenter retrospective study. BMC Cancer 23:283, 2023.
PubMed
11) Kadono T, Yamamoto S, Hirose T, et al:Safety and short-term efficacy of preoperative FOLFOX therapy in patients with resectable esophageal squamous cell carcinoma who are ineligible for cisplatin. Esophagus 20:109-115, 2023.
PubMed
12) Ancona E, Ruol A, Santi S, et al:Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma:final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 91:2165-2174, 2001.
 
13) 熊西, ほか:術前DCF療法中の発熱性好中球減少症に対する至適一次予防法. 第76回日本食道学会学術集会 2022.
 
14) Kato K, Ito Y, Nozaki I, et al:Parallel-Group Controlled Trial of Surgery Versus Chemoradiotherapy in Patients With Stage I Esophageal Squamous Cell Carcinoma. Gastroenterology 161:1878-1886.e2, 2021.
 
15) Ito Y, et al:A single-arm confirmatory study of definitive chemoradiotherapy (dCRT) including salvage treatment in patients (pts) with clinical (c) stage II/III esophageal carcinoma (EC) (JCOG0909). J Clin Oncol 36(suppl_4051):2018.
 
16) Ishida K, Ando N, Yamamoto S, et al:Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus:a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 34:615-619, 2004.
PubMed
17) Hamamoto Y, Sakakibara N, Nagashima F, et al:Treatment selection for esophageal cancer:evaluation from a nationwide database. Esophagus 15:109-114, 2018.
PubMed
18) Conroy T, Galais MP, Raoul JL, et al:Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17):final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305-314, 2014.
PubMed
19) Jingu K, Takahashi N, Murakami Y, et al:Is Concurrent Chemotherapy With Radiotherapy for Esophageal Cancer Beneficial in Patients Aged 80 Years or Older? Anticancer Res 39:4279-4283, 2019.
PubMed
20) Sun JM, Shen L, Shah MA, et al:Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590):a randomised, placebo-controlled, phase 3 study. Lancet 398:759-771, 2021.
PubMed
21) Doki Y, Ajani JA, Kato K, et al:Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. N Engl J Med 386:449-462, 2022.
PubMed
22) Yamamoto S, Kawakami H, Kii T, et al:Randomized phase II study of docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma refractory to fluoropyrimidine- and platinumbased chemotherapy:OGSG1201. Eur J Cancer 154:307-315, 2021.
PubMed
23) Kato K, Muro K, Ando N, et al:A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus:The Japan Clinical Oncology Group (JCOG) Trial (JCOG9905-DI). Esophagus 11:183-188, 2014.
 
24) Zurlo IV, Pozzo C, Strippoli A, et al:Safety and Efficacy of a First-Line Chemotherapy Tailored by G8 Score in Elderly Metastatic or Locally Advanced Gastric and Gastro-Esophageal Cancer Patients:A Real-World Analysis. Geriatrics (Basel) 7:107, 2022.
PubMed
P.411 掲載の参考文献
1) van Hagen P, Hulshof MC, van Lanschot JJ, et al:Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074-2084, 2012.
 
2) Klevebro F, Johnsen G, Johnson E, et al:Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction:A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol 41:920-926, 2015.
PubMed
3) Sunde B, Klevebro F, Johar A, et al:Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial). Br J Surg 106:1452-1463, 2019.
PubMed
4) A comparison of chemotherapy and radiotherapy as adjuvant treatment to surgery for esophageal carcinoma. Japanese Esophageal Oncology Group. Chest 104:203-207, 1993.
PubMed
5) Ando N, Iizuka T, Ide H, et al:Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus:a Japan Clinical Oncology Group Study-JCOG9204. J Clin Oncol 21:4592-4596, 2003.
 
6) Ando N, Kato H, Igaki H, et al:A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol 19:68-74, 2012.
 
7) 宇良, ほか:「進行食道がんに対する術前 Docetaxel, Cisplatin, 5-FU 併用療法の安全性を確認する臨床第II相試験」2009 第63回日本食道学会.
 
8) Hara H, Tahara M, Daiko H, et al:Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci 104:1455-1460, 2013.
PubMed
9) Sjoquist KM, Burmeister BH, Smithers BM, et al:Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma:an updated meta-analysis. Lancet Oncol 12:681-692, 2011.